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HSP27 AND CHEMOTHERAPY-INDUCED AUTOPHAGY AS BIOMARKERS
IN OSTEOSARCOMA

John Andrew Livingston, M.D.

Advisory Professor: Eugenie S. Kleinerman, M.D.

Survival for patients with osteosarcoma has not improved for > 30 years. Despite
aggressive multi-agent chemotherapy combined with surgical resection, a significant
fraction of patients with localized disease relapse after optimal treatment. We evaluated
the occurrence of cytoplasmic LC3B (light chain 3B)-positive puncta (a marker of
autophagy) and presence of HSP27 (heat shock protein 27) in cancer cells within pretreatment biopsy, post-treatment surgical resection, and metastatic osteosarcoma
specimens by immunohistochemistry in 260 patients. LCB3+ puncta expression was seen
in 34% of pre-treatment. 50% of resection, and 67% of metastasis samples. Sixty-six
percent of all specimens were scored positive for HSP27 (85% of pre-treatment. 52% of
resection, and 50% of metastasis samples). Among 215 patients with localized disease,
pre-treatment HSP27 expression was associated with inferior overall survival (adjusted
HR 26.7, p=0.0263) as well as at resection following chemotherapy (adjusted HR 1.85,
p=0.039). Lack of LC3B-puncta expression was an independent poor prognostic marker
at resection (adjusted HR 1.75, p=0.045). Patients with LC3B+/HSP27- tumors at
resection had the best prognosis whereas patients with LC3B-/HSP27+ osteosarcoma had
the worst long-term survival. Neither HSP27 nor LC3B expression correlated with tumor
necrosis. These findings indicate that HSP27 expression is a negative prognostic
iv

biomarker in osteosarcoma. Conversely, presence of autophagy following neoadjuvant
chemotherapy, as measured by LC3B-puncta, predicts longer overall survival in
osteosarcoma patients with localized disease.
We additionally evaluated the significance of chemotherapy-induced autophagy in
2 human osteosarcoma cell lines: LM7 and CCH-OS-D. Both doxorubicin (DOX) and
cisplatin (CDDP) were found to induce autophagy. In LM7 cells, autophagy inhibition
with hydroxychloroquine (HCQ) prior to chemotherapy resulted in a trend towards
decreased viability consistent with a cytoprotective role of autophagy. In CCH-OS-D
cells, autophagy inhibition prior to DOX significantly decreased chemosensitivity
suggesting a cytotoxic role of autophagy in this setting. The post-treatment expression of
phosphorylated HSP27 was increased in LM7 and decreased in CCH-OS-D following
DOX or CDDP. These findings support a dual role of chemotherapy-induced autophagy
and potential application of pHSP27 as a predictive biomarker of autophagy inhibitors in
osteosarcoma.
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I. Background:
Current Therapies for Osteosarcoma
Bone sarcomas are rare, making up 0.2% of all cancers.1 Osteosarcoma is the
most common bone sarcoma with approximately 1000 new cases per year in the U.S. and
predominantly effects adolescents and young adults.2 Prior to the introduction of multiagent chemotherapy, survival for patients with osteosarcoma was extremely poor with
long-term survival <20%.3 Up to 90% of patients developed metastatic disease following
surgery alone, leading to the hypothesis that the majority of patients have subclinical
micrometastatic disease at presentation. With the addition of perioperative chemotherapy
beginning in the 1960s and 1970s, survival for patients with localized osteosarcoma has
now improved to 60-65%.4 While chemotherapy plays an integral role in curative
treatment for patients with osteosarcoma, chemotherapy alone is inadequate. Patients who
do not undergo surgical resection of their disease will eventually relapse.5 These
observations have informed the current treatment paradigm for osteosarcoma which
consists of preoperative combination chemotherapy with MAP (cisplatin, doxorubicin,
and high-dose methotrexate) followed by limb-sparing surgery (when feasible) with
pathologic response assessment and subsequent MAP chemotherapy (Figure 1). Despite
these advances, there is still a significant fraction of patients who relapse and die of
pulmonary metastasis,6 and there have been no significant improvements in overall
survival for >30 years.4, 7
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Pre-op Chemotherapy (MAP)

Pre-treatment Biopsy

Post-op Chemotherapy (MAP)

Limb Salvage
Pathologic Response
Assessment
(% tumor necrosis)

Possible Relapse/
Metastasis

Figure 1. Standard treatment schema for localized osteosarcoma. Tumor tissue is
obtained prior to treatment, at resection, and at relapse (blue dots).
The prognosis for patients with metastatic disease is particularly poor and
treatment of recurrent/metastatic disease remains a challenge. Patients with primary
metastatic disease (those presenting with overtly metastatic disease at diagnosis) have a
5-year survival of approximately 30-50%8, 9 and those with metastatic recurrence have
even lower 5-year survival of 15-20%.10 Pulmonary metastasectomy can be curative in
patients with limited/resectable pulmonary disease whereas unresectable metastatic
disease (such as multiple osseous metastases or extensive pulmonary disease) is likely
incurable. While a number of chemotherapeutic regimens have been evaluated either
retrospectively or in the context of clinical trials, response rates range from 10-40% with
4-month progression-free survival rates ranging from 25 to > 45% (selected studies in
Table 1). The pooled outcomes for patients with recurrent osteosarcoma enrolled on 7
phase 2 clinical trials through the Children’s Oncology Group (COG) and its predecessor
cooperative groups are even more discouraging.11 In each individual trial, the drugs tested
were deemed to be inactive. The event-free survival (EFS) for patients with measurable
disease was 12% at 4 months (95% CI, 6% - 19%) with no significant difference in EFS
based upon patient demographics or the number of prior treatment regimens. For patients
with pulmonary metastasis who were rendered disease free by surgery and were treated
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on study AOST0221 (inhaled GM-CSF), the EFS was significantly better than those with
unresectable disease but remained low, 20% at 12 months (95% CI, 10-34%). Another
recent study of advanced bone sarcoma patients treated in phase I clinical trials at MD
Anderson Cancer Center re-demonstrated the overall poor outcomes and lack of effective
therapies for these patients. This included pediatric and adult osteosarcoma patients
treated across 14 unique protocols and showed no response to any of the cytotoxic,
targeted, or biologic agents used.12 The 4-month progression-free survival (PFS) was
26% for patients with recurrent osteosarcoma.
Chemotherapy Regimen
Gemcitabine + docetaxel

Outcome
PR: 3/10; SD 1/10

Study
Navid F, et al. Cancer.
2008.13
Cyclophosphamide
+ PFS at 4 months: 42%
Massimo B, et all. Cancer.
etoposide
2009.14
Cyclophosphamide
+ PR: 2/18
Saylors RL, et al. JCO.
topotecan
2001.15
Ifosfamide + etoposide
PR or CR: 3/8
Miser JS, et al. JCO. 198716
Ifosfamide + carboplatin + ORR: 51% (all sarcomas)
Van Winkle P, et al. Pediatr
etoposide
Blood Cancer. 2005.17
High-dose ifosfamide
ORR 20%
Palmarini E, et al. ASCO,
PFS at 4mo: 25%
2015.18
Sorafenib + everolimus
PFS at 6 mo: 45%
Grignani G, et al Lancet
Onc. 2015.19
Table 1. Treatment outcomes for relapsed/metastatic osteosarcoma. Complete response
(CR), objective response rate (ORR), progression-free survival (PFS), partial response
(PR), stable disease (SD).
Given the adverse outcomes and limited efficacy of treatment in the
recurrent/metastatic setting as well as the lack of promising agents in early-phase
development, it is important to identify patients with a high-likelihood of metastatic
relapse and death for consideration of clinical trial participation in studies that combine
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molecular biomarkers and targeted therapies, either in the neoadjuvant or adjuvant
setting, to improve the efficacy of standard chemotherapy for osteosarcoma. As such, the
identification of novel prognostic biomarkers either at diagnosis or resection following
neoadjuvant chemotherapy is an unmet need in osteosarcoma.

Prognostic Markers in Osteosarcoma
Due to the potential for relapse amongst patients treated with standard therapy,
several studies have sought to identify prognostic markers in patients with osteosarcoma.
To date, stage at presentation (localized vs metastatic) and pathologic response to
neoadjuvant chemotherapy (assessed by percent necrosis at the time of surgical resection)
remain the most widely accepted and clinically utilized prognostic factors. Other clinical
and pathologic factors have been explored as they relate to metastasis-free and overall
survival including age at diagnosis, sex, stage at presentation, tumor location, tumor size,
histologic subtype, surgical margins, and serum markers such as lactate dehydrogenase
(LDH) level or alkaline phosphatase levels among others.20-23 For example, in one large
retrospective cohort of 1,702 patients with high-grade osteosarcoma treated on
neoadjuvant cooperative group protocols, older patient age at diagnosis (≥ 40 years),
axial tumor site, larger tumor size (for extremity tumors), and presence of primary
metastasis were associated with inferior overall survival.21 Treatment-related factors
including response to chemotherapy and the extent of surgery (incomplete vs
macroscopically complete) were also shown to be significant. In multivariate analysis,
residual tumor (HR 4.01, p< 0.0001) and poor response to chemotherapy (HR 2.44, p<
0.0001) were identified as key prognostic factors for overall survival.
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Identifying patients with localized (i.e. non-metastatic) disease that are at highrisk for relapse is clinically relevant and has informed the design of adjuvant therapy
trials in osteosarcoma. Pathologic response to chemotherapy, as assessed by percent
tumor necrosis on the primary resection specimen, is a well-established prognostic factor
in osteosarcoma.24 Poor response has been defined as <90% tumor necrosis in most
studies, however this cutoff may vary. In early studies of preoperative chemotherapy,
patients with a poor response to MAP chemotherapy had significantly worse outcomes.25,
26

These findings were confirmed in an initial literature review of studies that included

non-metastatic high-grade osteosarcoma patients published between 1973-1992 where
only tumor necrosis following preoperative chemotherapy was found to have independent
prognostic significance.27 In a subsequent systematic review including studies from 19922006, poor response to chemotherapy (pooled relative risk (RR) of death or recurrence
2.37, 95%CI 2.07-2.70), larger tumor volume (pooled RR 1.36, 95%CI 1.18-1.58) and
ablative surgery as compared to limb salvage (pooled RR 2.18, 1.58-3.00) were all
identified as predictors of adverse outcomes.28 However, the authors noted that a pooled
analysis was challenging due the heterogeneity of the prognostic factors analyzed across
studies.
With the identification of tumor necrosis as a prognostic biomarker in
osteosarcoma, multiple clinical trials have sought to intensify either preoperative
chemotherapy to improve pathologic response rates or modify postoperative therapy to
improve outcomes among poor responders. Intensification of preoperative therapy can
result in higher rates of “good necrosis,” but this strategy results in greater toxicity
without clear survival benefit. In a phase II study evaluating intensification of

5

preoperative chemotherapy, the addition of ifosfamide to a standard doxorubicin/cisplatin
backbone with autologous stem cell rescue resulted in an improvement in the objective
rate of tumor necrosis but resulted in unacceptable toxicity and no significant
improvement in survival.29
The role of tailored or modified post-operative therapy for patients with poor
tumor necrosis remains controverted. The initial rationale for modification of
postoperative chemotherapy amongst poor responders was established in the 1970s when
primary (preoperative) therapy consisted of a less active drug combination than current
MAP chemotherapy.26 In subsequent studies from the Rizzoli Institute, intensification of
postoperative chemotherapy amongst poor responders improved survival: patients
received neoadjuvant chemotherapy with 2 cycles of high-dose methotrexate (HD MTX),
intra-arterial cisplatin, and intravenous doxorubicin followed by surgical resection; poor
responders (<90% tumor necrosis) went on to receive additional chemotherapy with
ifosfamide and etoposide (I/E) in addition to MAP.30 The 5-year continuous disease-free
survival (CDFS) was 63%, with no significant difference between good and poor
responders. These findings have informed the subsequent treatment paradigm for patients
with poor response to MAP chemotherapy. In one large retrospective series of adult
patients with osteosarcoma treated at MD Anderson Cancer Center, the addition of highdose ifosfamide to postoperative therapy increased the CDFS amongst poor responders to
67%.31, 32 These findings were validated in an updated series of adult patients treated
within the same center.33 A recent large international randomized clinical trial has called
the utility of this approach into question, however. In the EURAMOS-01 study, 618
patients with poor tumor necrosis following preoperative MAP chemotherapy were
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randomized to receive either MAP or MAP plus ifosfamide and etoposide (MAPIE).34
Toxicity was noted to be higher in the MAPIE group and EFS did not differ between
treatment groups (HR 0.98, 95% CI 0.78 – 1.23), leading investigators to conclude that
the results do not support the addition of I/E to postoperative therapy for patients with
poor response and that “new strategies are required to improve outcomes in this setting.”
Similarly, a retrospective analysis of assessing the prognostic value to histologic response
to therapy between a historic regimen (CCG-78235) vs increased intensity induction
therapy (INT-013336) found that while histologic response predicted outcomes across
studies (p <0.0001), there was an inverse relationship between the predictive value of
tumor necrosis and the intensity of induction therapy.37 Stated another way, the difference
in outcomes between good and poor responders was less dramatic with modern
intensified chemotherapy as compared to prior regimens (10y EFS 70.8% vs 58.4% in
good v poor responders respectively in INT-0133 as compared to 75.4% vs 39.9% in
CCG-782). Thus the authors concluded that their findings “highlight the need for novel
markers” to develop treatment strategies in future trials.
To date, there are no established predictive biomarkers of response to MAP
chemotherapy in osteosarcoma. Identifying poor risk patients at diagnosis would allow
for a window trial approach with correlative biomarkers. Similarly, additional factors that
allow for risk stratification independent of tumor necrosis would be valuable in informing
future studies of adjuvant therapy in osteosarcoma. Therefore, research to identify novel
biomarkers (both predictive and/or prognostic), potential targets focusing on mechanisms
of chemoresistance, and opportunities to enhance efficacy/sensitivity to standard agents
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(MAP) is imperative to inform clinical trial design and improve outcomes for patients
with osteosarcoma.

Autophagy in Cancer and Cancer Treatment
Autophagy is a conserved physiologic process of cellular catabolism that allows
the degradation and recycling of intracellular organelles, proteins, and macromolecules in
order to maintain homeostasis during times of nutrient depravation and cellular stress.38
The process of sequestering and breakdown of these cellular components through
lysosoamal degradation is termed macroautophagy (referred to as autophagy henceforth).
In this process, autophagy-related proteins sequester macromolecules to be degraded into
double-membrane vesicles (termed autophagosomes). Autophagosomes fuse with the
lysosome to form the autolysosome in which the macromolecules and organelles are then
broken down into amino acids, nucleic acids, and fatty acids which can be used to
maintain adenosine triphosphate (ATP) synthesis and support other key anabolic
pathways. Macroautophagy has been the primary focus for studies of autophagy and
autophagy inhibition in cancer. This differs from microautophagy (a nonselective
lysosomal degradation by direct engulfment)39, chaperone-mediated autophagy (in which
chaperones in the cytosol facilitate lysosomal proetolysis)38, and mitophagy (which refers
to the degradation of mitochondria by autophagy).40
Autophagy serves a dual role, either as a mechanism of cell survival or of cell
death. As a cytoprotective mechanism, autophagy promotes cell survival in the setting of
nutrient deprivation or other stress. Alternatively uncontrolled/excess autophagy can lead
to cell death through apoptosis or an alternate cell death pathway termed “autophagic cell
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death.” For example, studies have shown that knockdown of key autophagy (ATG) genes
can promote both apoptotic and non-apoptotic cell death, suggesting that the role of
autophagy is cytoprotective.39 Conversely, multiple lines of evidence support the
rationale for autophagy as an alternate cell death pathway: 1) overexpression of
autophagy proteins such as Beclin 1 or Atg1 can lead to cell death,41, 42 2) cells that are
deficient in apoptosis can undergo ATG-dependent cell death,43, 44 and 3) pharmacologic
inhibition of autophagy may prevent cell death in certain settings.45, 46 This duality is
particularly important in cancer and has implications for both carcinogenesis and cancer
treatment.
In cancer, the dual role of autophagy is often referred to as the “autophagy
paradox.” In the early stage of tumorigenesis, autophagy has been shown to act as a
tumor suppressor. Inhibition of autophagy through allelic deletion of Becn1 in genetic
mouse models (BENC+/-) promotes tumorigenesis and results in a high incidence of
spontaneous tumors.47,

48

Additionally, autophagy inhibition can lead to increased

metabolic stress and genomic instability which can promote tumorigenesis and tumor
progression.49 Conversely, activation and up regulation of autophagy is thought to
contribute to tumor growth, tumor progression, and treatment resistance by promoting
cell survival during periods of nutrient deprivation, chemotherapy, or radiation-induced
stress.50 Because of this apparent paradox, there has been significant controversy
regarding the role of autophagy modulation in cancer therapy.
Autophagy markers such as LC3B puncta, p62/sequestosome 1 (SQSTM1),
Beclin 1, and presence of autophagic vesicles or autophagosomes (evaluated by
transmission electron microscopy [TEM]) have been explored as potential predictive and
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prognostic biomarkers in multiple cancer types. For example, in a series of 12 patients
with melanoma treated on a phase II trial of sorafenib and temozolimide, patients whose
tumors had a high “autophagic index” (defined as ≥6 autophagic vesicles per cell on EM)
were less likely to respond to treatment and had shorter survival as compared to those
with a low autophagic index.51 In another series, the presence of high LC3 expression in
pancreatic adenocarcinomas at time of pancreatoduodenectomy was associated inferior
disease-free survival.52 In colon cancer, overexpression of Beclin 1 has been associated
with inferior overall survival amongst patients receiving adjuvant 5-fluorouracil
chemotherapy.53 While the presence of autophagy appears to be a negative prognostic
marker in most cancer types, high expression of LC3 and Beclin 1 has been associated
with improved response rate and superior overall survival in patients with ovarian
cancer.54 In breast cancer, studies are conflicting. In one study, the presence of LC3B (but
not Beclin 1) in residual tumors following neoadjuvant chemotherapy predicted inferior
relapse-free survival (RFS; multivariate HR 1.88, 95% CI 1.14-3.08) and overall survival
(OS; multivariate HR 2.43, 95% CI 1.26-4.67).55 A subsequent study found that when
combined, the presence of LC3B+ puncta and nuclear HMGB1 expression in women
with breast was associated with significantly improved metastasis-free survival following
adjuvant chemotherapy (HR 0.49, 95% CI 0.26-0.89).56 Conflicting studies such as these,
call into question the importance of evaluating autophagy in a context-dependent manner
and additionally raise concerns about the methodology for evaluating autophagy markers
in patient samples. As autophagy is a dynamic process, it is important to distinguish
between static measurements of autophagy from those which measure autophagic flux.
This has been a major limitation of prior studies. Expert guidelines recommend that the
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use of autophagy markers such as LC3B be accompanied by assays to estimate overall
autophagic flux.57 In the study by Ladoire et al., the presence of cytoplasmic LC3B
puncta was shown to have an inverse correlation with p62 staining, supporting the
authors conclusion that in their study population high LC3B puncta reflects increased
autophagic flux.56 No studies have evaluated the predictive or prognostic significance of
autophagy markers in osteosarcoma.
A wide range of current cancer drugs have been shown to modulate autophagy.
For example, cytotoxic chemotherapies, hormonal therapies, and targeted therapies such
as mTOR (mammalian target of rapamycin) inhibitors, HDAC (histone deacetylase)
inhibitors, and multiple tyrosine kinase inhibiors (TKIs) have all been shown to induce
autophagy in various cancer types.58 The listing of approved agents by the United States
Food and Drug Administration (FDA) that inhibit autophagy is much shorter, including
the antimalarial drugs chloroquine and hydroxychloroquine (HCQ) which inhibit
lysosomal degradation. Several clinical trials have been conducted or are currently
underway utilizing HCQ to inhibit autophagy.59 However, an important question remains:
is autophagy inhibition beneficial or potentially detrimental?
The role of autophagy in cancer is context-dependent and can vary based upon
tumor type, stage (premalignant vs invasive), and cancer therapy.60 Recently studies have
suggested that the role of autophagy and therefore the efficacy of autophagy inhibition
may be dependent on p53 status. In a pancreas cancer genetically engineered mouse
model (GEMM) of Kras-mutant, Trp53

-/-

pancreatic adenocarcinoma, loss of autophagy

via tumor specific Atg5 or Atg7 deletion or pharmacologic inhibition with
hydroxycloroquine accelerated the development of pancreatic ductal adenocarcinomas.61
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These findings called into question the safety of autophagy inhibition in patients with
TP53-mutant cancers.62 Subsequent studies have refuted these findings based upon a
pancreas-specific Kras-mutant Trp53+/− GEMM.63 This model allows for adult p53 loss
of function via loss of heterozygosity (LOH) (rather than embryonic loss of p53) and is
thought to more accurately recapitulate pancreatic tumor progression in humans. In this
study, Atg5 deletion resulted in tumor suppression, with an increase premalignant lesions
but preventing progression to pancreatic ductal adenocarcinoma and leading to prolonged
survival. Taken together, these findings suggest that p53 status alone does not determine
the role of autophagy in cancer. Rather, additional studies are needed to identify potential
biomarkers that correlate with the role of autophagy in specific context (cancer type,
therapy, stage) and may predict the therapeutic benefit of autophagy modulation.

Autophagy in Osteosarcoma
In osteosarcoma, most studies have focused on chemotherapy-induced autophagy
as a mechanism of chemoresistance.64 Cisplatin, doxorubicin, and methotrexate have all
been shown to induce autophagy in osteosarcoma cells, which then promotes tumor cell
survival by decreasing sensitivity to chemotherapy.65-67 Autophagy inhibition, either via
knockdown of key autophagy genes such as Beclin 168 or pharmacologic inhibition with
compounds such as 3-methyladenine,67 bafilomycin A1,69 or chloroquine66 have been
shown to decrease cell proliferation and increase apoptosis in osteosarcoma cells treated
with doxorubicin or cisplatin. Further, MAP chemotherapy results in the upregulation of
high mobility group box 1 protein (HMGB1) in osteosarcoma in vitro and has been
suggested as a potential therapeutic target in osteosarcoma.70, 71
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Our lab has previously shown a dual role for chemotherapy-induced autophagy in
osteosarcoma.72,

73

Gemcitabine (GCB) treatment of human LM7, CCH-OS-D, and

murine K7M3 cells in vitro and osteosarcoma lung metastases in vivo resulted in the
formation of autophagic vesicles, conversion of LC3I to LC3II, and upregulation of
Beclin 1 in both cells and tumor tissues as well as degradation of p62 and the formation
of acidic vesicular organelles in tumor cells consistent with induction of autophagy. To
evaluate the role of autophagy, we analyzed cell viability following treatment with
chemotherapy combined with inhibition of autophagy by BECN1 or ATG knockdown and
pharmacologic inhibition with hydroxychloroquine (HCQ). In LM7, chemotherapy in
combination with autophagy inhibition by BECN1 knockdown or HCQ treatment resulted
in decreased viability suggesting a cytoprotective role for autophagy. Conversely,
autophagy inhibition prior to chemotherapy resulted in increased cell viability of CCHOS-D and K7M3 cells consistent with cytotoxic autophagy.

Phosphorylated HSP27 as a Potential Biomarker of Chemotherapy-induced
Autophagy in Osteosarcoma
We completed a human phosphokinase array to identify differentially expressed
proteins and phosphoproteins at baseline and following treatment with GCB in
osteosarcoma cell lines exhibiting opposing effects of autophagy and autophagy
inhibition. Post-treatment expression of phosphorylated heat shock protein 27 (pHSP27)
was significantly different between LM7 and CCH-OS-D cells following gemcitabine
exposure and appeared to correlate with the role of chemotherapy-induced autophagy.
Induction of pHSP27 following treatment with GCB correlated with a cytoprotective role
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of autophagy and reduced chemosensitivity, while a failure to induce pHSP27 correlated
with a cytotoxic role of autophagy. Inhibition of autophagy in cells with increased
expression of pHSP27 following drug exposure resulted in increased osteosarcoma cell
killing; conversely inhibition of autophagy in cells with decreased expression of pHSP27
following treatment decreased osteosarcoma cell killing.73 These findings were validated
in K7M3 cells treated with 9-nitrocamptothecin (9-NC). Previously, our lab has shown
that inhibiting autophagy in K7M3 cells prior to treatment with 9-NC increases
cytotoxicity whereas autophagy inhibition prior to treatment with GCB reduced
cytotoxicity as compared to GCB alone.72 In a subsequent study, we found that this effect
again correlated with the post-treatment expression of pHSP27: 9-NC resulted in
induction of pHSP27 (and correlated with cytoprotective autophagy) whereas pHSP27
was decreased following GCB treatment in K7M3 (correlating with cytotoxic
autophagy). The correlation between pHSP27 expression and the role of chemotherapyinduced autophagy in osteosarcoma was independent of cell line, species of origin, or
specific chemotherapy (summarized in Table 2). Taken together, our findings suggest
that pHSP27 may be a biomarker to predict the benefit of autophagy inhibitors in the
treatment of osteosarcoma.
Cell Line

Chemotherapy
pHSP27 expression Role of Autophagy
LM7
GCB
Increase
Cell survival
CCH-OS-D
GCB
Decrease
Cell death
K7M3
GCB
Decrease
Cell death
K7M3
9-NC
Increase
Cell survival
MG63
GCB
No change
No effect
Table 2. Correlations between post-treatment expression of pHSP27 and the role of
chemotherapy-induced autophagy in vitro. GCB – gemcitabine, 9-NC – 9nitrocamptothecin.
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In the proposed model, treatment with chemotherapy in osteosarcoma results in an
induction of autophagy. This can be accompanied by an increase in pHSP27 (Figure 2, a)
which is associated with chemoresistance and cytoprotective autophagy or conversely, a
degradation of pHSP27 associated with cytotoxic autophagy and autophagic cell death
(b). In the first scenario, autophagy inhibition with drugs such as HCQ results in
increased chemosensitivity (Figure 2, c). In the second, autophagy inhibition would result
in decreased drug sensitivity (d).
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Figure 2. Proposed model for chemotherapy-induced autophagy and pHSP27 in
osteosarcoma. (a) Increased pHSP27 expression following chemotherapy correlates with
cytoprotective autophagy; (b) Decreased pHSP27 correlates with cytotoxic autophagy.
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Figure 2 (continued). (c) Autophagy inhibition increases drug sensitivity (decreased cell
viability). Viability studies show a decrease in LM7 viability with the combination of
HCQ and GCB as compared to GCB alone; (d) Autophagy inhibition decreases drug
sensitivity (increased cell viability) in osteosarcoma cells with decreased post-treatment
pHSP27 expression. Viability studies show an increase in CCH-OS-D viability with the
combination of HCQ and GCB as compared to GCB alone. Cell viability data reproduced
with permission, courtesy Janice Santiago-O’Farrill PhD.
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Heat shock Protein 27 (HSP27) in Cancer and Cancer Treatment
Heat shock proteins (HSPs) are a highly conserved class of cytoprotective
proteins whose synthesis is stimulated by heat shock (as their name implies) as well as
other environmental and physiologic stressors. Heat shock protein 27 (also known as
HSPB1) is a small HSP (molecular weight 27 kD) that is found in both normal cells and
human cancers.74 Gene expression data from the Cancer Genome Atlas (TCGA) and the
Genotype-Tissue Expression Project (GTEx)75 show that HSP27 is highly expressed
across a range of normal tissues and tumor types including soft tissue sarcomas, with
uterine and soft tissue leiomyosarcoma being most notable (Figure 3; ULMS and
STLMS, respectively). Notably, osteosarcoma expression data is not included in the
TCGA.

Figure 3. HSP27 expression across normal tissues and multiple cancer subtypes. The
results presented here are in part based upon data generated by the TCGA Research
Network: http://cancergenome.nih.gov/.
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In cancer, HSP27 expression can be induced by cytotoxic drugs and protects cells
from apoptotic cell death. Overexpression of HSP27 is a poor prognostic biomarker in
multiple cancers including gastric, liver, prostate, rectal and breast, and is additionally a
marker of chemotherapy resistance in breast cancer and leukemia.76, 77
HSP27 can undergo post-translational modification via serine phosphorylation;
human HSP27 is phosphorylated at serine15, serine-78, and serine-82 by MAPKAP
kinase 2/3 via the activation of the P38 MAPK pathway.78 Phosphorylation is a dynamic,
reversible process that can affect structure, oligimerization, and function. Heat shock as
well as other stressors have been shown to induce phosphorylation. Interestingly, early
studies noted that agents such as tumor necrosis factor (TNF) and leukemia inhibitory
factor only induced HSP27 phosphorylation in cells that were sensitive to the agents.74
Similarly, in human breast cancer cells, phorbol ester induces HSP27 phosphorylation
and inhibits cell growth.79 More recently, pHSP27 has been associated with gemcitabineresistance in pancreatic cancer cells as well as 5-fluorouracil resistance in colorectal
cancer.80,

81

As a prognostic marker, pHSP27 expression is inversely correlated with

tumor size and stage and was noted to decrease at progression in hepatocellular
carcinoma82 and was shown to correlate with HER-2 status and node positivity in breast
cancer.83
While previously unactionable, several strategies are being developed to target
heat shock proteins in cancer therapy.84 Recent studies with the novel HSP27 antisense
oligonucleotide OGX-427 have shown promise in multiple tumor types including reports
of increased chemosensitivity to GCB in pancreatic cancer85, erlotinib and chemotherapy
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in NSCLC86, and increased responses to docetaxel in prostate cancer87. However, only
limited preclinical data exists for the use of OGX-427 in osteosarcoma and no sarcoma
patients were included in the phase I trials.88

Heat Shock Protein 27 in Osteosarcoma
Two small series have evaluated the expression and prognostic significance of
HSP27 in osteosarcoma. HSP27 is overexpressed in 22-24% of patients at baseline and
33-37% at resection following neo-adjuvant chemotherapy.89,

90

Overexpression of

HSP27 in pretreatment biopsy samples evaluated in 54 patients was associated with
inferior overall survival in univariate analysis (HR 3.95, [1.67-9.34]) and when adjusted
for tumor size and histologic subtype (HR 3.26, [1.28-8.31]).89 In a second series from
the same group examining the prognostic significance of multiple HSPs (27, 47, 60, 70,
90α, 90β), only HSP27 overexpression at biopsy (p=0.0021) and HSP27 and HSP70
expression at surgery (p=0.045, and p=0.018 respectively) were significantly associated
with poor prognosis.90 Similarly, HSP27 overexpression at biopsy was associated with
inferior overall survival in a multivariate analysis (adjusted HR 2.63, [1.14-6.06]),
although presumably this series included some of the same patients as the initial study.
As predictive biomarkers, HSP72 expression by immunohistochemistry91 and antibodies
to HSP9092 in patient sera prior to initiation of therapy have both been shown to correlate
with better responses to neoadjuvant chemotherapy. The utility of HSP27 as a potential
predictive biomarker of chemotherapy response has not been assessed in osteosarcoma.
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Hypothesis and Aims
Based upon preclinical data showing a dual role for chemotherapy-induced
autophagy in osteosarcoma and the correlation between autophagy inhibition and
pHSP27 expression in vitro, my central hypothesis is that phosphorylated HSP27
determines the role of autophagy in osteosarcoma and modulates response to preoperative
chemotherapy. Therefore, HSP27, pHSP27, and/or autophagy may pose novel
biomarkers and potential therapeutic targets to improve the efficacy of standard MAP
chemotherapy in patients with osteosarcoma.

In order to test this hypothesis, the following specific aims were studied:
Aim 1. To determine if autophagy is induced in osteosarcoma tumor specimens following
preoperative chemotherapy and correlates with pathologic response, prognosis, and
HSP27/pHSP27 expression.

Aim 2. To determine whether standard chemotherapy can result in either cytotoxic or
cytoprotective autophagy in osteosarcoma cell lines and determine whether pHSP27
expression correlates with the cytoprotective function of chemotherapy-induced
autophagy following treatment with doxorubicin or cisplatin
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II. Materials and Methods:
Patients
The study population for Aim 1 included 260 pediatric and adult patients with
osteosarcoma evaluated at the University of Texas MD Anderson Cancer Center between
1985 and 2012 with tissue specimens included on an institutional tissue microarray
(TMA) that contains 394 specimens. In all cases, the diagnosis was established according
to the World Health Organization Classification of Tumors by an expert sarcoma
pathologist. 93 Patients with extraskeletal osteosarcoma were specifically excluded as this
is considered a separate entity. Clinical data was collected by retrospective chart review.
Institutional Review Board approval was obtained for this study and was exempt from
requiring informed consent.

Construction of tissue microarrays
Decalcified FFPE tissue blocks from osteosarcoma pretreatment biopsies and
surgical resection specimens (resected primary tumors and resected metastasis) were
retrieved from the MD Anderson institutional tumor bank. Hematoxylin/eosin stained
slides from each block were reviewed by a sarcoma pathologist to identify tumor areas.
Tissue microarrays (TMAs) were constructed with 0.6mm diameter tissue cores from
representative tumor areas from the FFPE blocks.

Immunohistochemical Studies
Four-micron thick unstained slides were prepared from formalin-fixed paraffinembedded decalcified human osteosarcoma tissue microarrays. Immunohistochemical
21

studies were performed using an autostainer (Bond III/Rx, Leica Biosystems, Buffalo
Grove, IL) with an anti-human HSP27 monoclonal antibody (1:1000, Thermo Fischer
Scientific, clone MA3-15) and LC3B (1:50, NanoTools/Axorra, clone 5F10).
Immunohistochemical labeling was independently scored by 2 trained sarcoma
pathologists, both of whom were blinded from the clinical data at the time of assessment.
Both percentage of tumoral labeling (0-100%) and the intensity of immunostaining [0
(negative), 1 (weak), 2 (moderate), 3 (strong)]was evaluated.
LC3B was evaluated using previously validated immunohistochemical methods94
with granular cytoplasmic or punctate staining assessed. Staining of >10% tumor cells
was considered positive for HSP27 or LC3B expression. In addition, median cut-points
(≥ vs < median % staining) and staining intensity (negative vs weak/moderate/strong)
were examined as prognostic factors.

OS cell lines and cell culture
LM7 is a human metastatic osteosarcoma cell line that was established in the
Kleinerman Lab by intravenous recycling the parental cell line (SAOS-2) through the
lungs of nude mice serially through 7 iterations. CCH-OS-D is a human osteosarcoma
cell line derived from an 18-year-old male with osteosarcoma lung metastasis. LM7, and
CCH-OS-D metastatic OS cell lines were cultured in Dulbecco’s modified Eagle medium
containing 10% fetal bovine serum supplemented with antibiotic and nonessential amino
acids. Cells were maintained in a humidified incubator with 5% CO2 at 37°C.
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Reagents and antibodies
Doxorubicin and cisplatin were obtained from the MD Anderson Cancer Center
pharmacy and dissolved in PBS to desired concentrations. HCQ was purchased from
Sigma Aldrich and dissolved with water to a concentration of 10mM. RIPA lysis buffer
(sc-24948) was purchased from Santa Cruz Biotechnology. The following antibodies
were used for Western blot analysis: Microtubule-associated protein 1 light chain LC3B
(NB600-1384) was purchased from Novus Biologicals. Beclin (sc-11427) and HSP27
(sc-13132) were purchased from Santa Cruz Biotechnology. SQSTM1/p62 (5114) was
obtained from Cell Signaling Technology. p-HSP27 (MAB23141) was purchased from
R&D Systems.

Cell viability
Cell viability, Western blot, and human phosphokinase arrays were completed
using the same methodology as prior studies from our lab.73 Cells were seeded in 12-well
plates with approximately 0.5 × 105 cells per well and allowed to attach overnight at
37°C, 5% CO2. Cells were then treated in the following conditions: doxorubicin,
cisplatin, HCQ, doxorubicin following HCQ pretreatment for 20 minutes, and cisplatin
following HCQ pretreatment; cells with no treatment served as controls. Cells were
trypsinized and viability was assessed by trypan blue exclusion assay using an automated
cell counter (Vi-cell, Beckman Coulter). The incubation time and drug concentrations are
specified in the results and respective figures.
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Human phospho-kinase Antibody Array Kit
LM7 and CCH-OS-D cells were treated with doxorubicin or cisplatin for 48
hours. Untreated cells were used as a control. The cells were collected and lysed using
the lysis buffer provided by the manufacturer, and protein concentration was determined
using the Bradford Protein Assay from Bio-Rad. After blocking, the membranes were
incubated with 400µg of protein overnight at 4°C. The membranes were washed and
incubated with Detection Antibody Cocktails. HRP- conjugated Streptavidin antibodies
and chemniluminescent detection reagents were used to visualize the protein.
Densitometry was completed using ImageJ software (https://imagej.nih.gov/ij/).

Western blot analysis
After treatment, whole cell lysates were prepared by lysing the cells with RIPA
lysis buffer for 30 minutes and centrifuging at 10,000 g at 4°C. Supernatants were
collected and protein concentration was determined using the Bio-Rad DC protein assay
kit (500-0113-0115). Equal amounts of protein were subjected to SDS-polyacrylamide
gels (SDS-PAGE) and transferred onto a nitrocellulose membrane. Membranes were
blocked in 5% milk or 5% bovine serum albumin for 1 hour and then incubated with
primary antibody against LC3 (1:1000) or p62 (1:1000). After overnight incubation with
primary antibodies, membranes were washed and incubated with anti-mouse (1:2000)
horseradish peroxidase linked whole antibody (from sheep, NA931V; GE Healthcare) or
anti-rabbit (1:2000) horseradish peroxidase linked whole antibody (from donkey,
NA934V; GE Healthcare) as a secondary antibody. Signal was detected using ECL
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reagents (GE Healthcare Life Science). β-actin or GAPDH were used as loading controls.
Densitometry was completed using ImageJ software (https://imagej.nih.gov/ij/).

Statistical analysis
Analyses of overall survival (OS) and relapse-free survival (RFS) were performed.
OS was defined as from the time of diagnosis to the time of death or to the time of last
contact. RFS was defined as from the time of surgery to the time of relapse or death,
whichever occurred first or to the time of last contact. The distributions of OS, and RFS
were estimated by the Kaplan-Meier method.95 Log-rank test was performed to test the
difference in survival between patient characteristics/biomarkers groups.96 Regression
analyses of survival data based on the Cox proportional hazard (PH) regression model
were conducted on OS and RFS.97 For the resection samples and good response,
landmark analysis method was used and time of surgery would be the starting points of
OS and RFS.98 Stepwise method was used to build a multivariate Cox PH regression
model. Functional form, PH assumption, and multicollinearity were examined.

The

correlation between two continuous factors was measured by Spearman correlation.99 The
Chi-square test and Fisher’s exact test were used to determine whether proportions of
patients with factors of interest were equal between patient characteristics/biomarkers
groups.100 Wilcoxon signed rank test was used to compare biomarker expression of
paired resection with synchronous metastatic samples, and paired resection with
metachronous metastatic samples. A two-sided p-value<0.05 was considered statistically
significant. SAS version 9.4 was used to carry out the computations. Experimental data
for cell viability studies were analyzed using Graphpad PRISM 6.0 software.
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III. Results
Clinical Characteristics
There were 215 patients with localized osteosarcoma at the time of diagnosis
(localized patients) and 45 patients with primary metastatic osteosarcoma (metastatic
patients). The age at diagnosis of all patients ranged from 4.9 to 90.8 with mean and
median of 24.2 and 18.3, respectively. Metastatic patients (mean= 24.8 years) were
slightly older than the localized patients (mean= 24.0 years). Tables 3 and 4 show the
clinical characteristics in all patients and by stage at presentation (localized disease and
metastatic disease).
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Factor
n Min
All patients
Age at diagnosis (years)
260 4.9
Tumor necrosis (%) (patients with pre-op
chemo)
241
0

Median

Mean

Max

SD

18.3

24.2

90.8

15.8

87.0

76.0

100

27.0

4.9

18.2

24.0

90.8

15.6

0

86.0

76.1

100

27.2

45

7.2

20

24.8

78.2

16.9

36

0

88

75.0

100

25.9

Localized disease at diagnosis
Age at diagnosis (years)
215
Tumor Necrosis (%) (patients with pre-op
chemo)
205
Metastatic disease at diagnosis
Age at diagnosis (years)
Tumor necrosis (%) (patients with pre-op
chemo)

Table 3. Clinical and pathologic characteristics by stage at presentation (continuous
factors).
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All patients
n (%)

Localized
Disease
n (%)

Metastatic
Disease
n (%)

Male
Female

153 (59)
107 (41)

126 (59)
89 (41)

27 (60)
18 (40)

Asian
Black
Hispanic
White

9 (3)
35 (14)
75 (29)
140 (54)

7 (3)
28 (13)
63 (29)
116 (54)

2 (4)
7 (16)
12 (27)
24 (53)

Osteoblastic
Chondroblastic
Fibroblastic
Telangiectatic
Dedifferentiated parosteal
Small cell
High grade surface
Other - high grade
Other intermediate/low grade
Radiation Induced Osteosarcoma
No
Yes
Primary Site
Femur
Tibia
Fibula
Humerus
Radius/ulna
Mandible
Rib/chest wall
Pelvis/acetabulum
Other upper extremity
Other lower extremity
Other axial skeleton

110 (42)
49 (19)
46 (18)
23 (9)
12 (5)
6 (2)
3 (1)
6 (2)
5 (2)

91 (42)
40 (19)
39 (18)
18 (8)
10 (5)
4 (2)
3 (1)
5 (2)
5 (2)

19 (42)
9 (20)
7 (16)
5 (11)
2 (4)
2 (4)

250 (97)
8 (3)

207 (96)
8 (4)

43 (100)

140 (54)
43 (17)
10 (4)
32 (12)
3 (1)
1 (0)
7 (3)
18 (7)
2 (1)
1 (0)
2 (1)

112 (52)
39 (18)
9 (4)
24 (11)
3 (1)
1 (0)
4 (2)
17 (8)
2 (1)
1 (0)
2 (1)

28 (62)
4 (9)
1 (2)
8 (18)

Factor
Gender

Race

Histologic Subtype

1 (2)

3 (7)
1 (2)

Table 4. Clinical and pathologic characteristics by stage at presentation (categorical
factors).
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Factor

All patients
n (%)

Localized
Disease
n (%)

Metastatic
Disease
n (%)

6 (2)
1 (0)
253 (97)

6 (3)
1 (0)
208 (97)

45 (100)

133 (55)
108 (45)

113 (55)
92 (45)

20 (56)
16 (44)

Grade
Low
Intermediate
High
Good response (patients receiving pre-op
chemo)
No
Yes

Table 4 (continued). Clinical and pathologic characteristics by stage at presentation
(categorical factors).
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Relapse-free and overall survival for osteosarcoma patients with localized disease
Amongst patients with localized disease at diagnosis, there were 122 relapses and
deaths during the follow-up period. Ninety-three patients are alive without relapse. Table
5 shows the log-rank test results for clinical characteristics related to relapse-free
survival. Patients with radiation induced osteosarcoma had inferior RFS than compared to
patients without radiation induced osteosarcoma (Figure 4, p=0.0050).
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Factor
Gender
Race
Histologic Subtype
Histologic Subtype (Osteoblastic)
Radiation Induced osteosarcoma
Primary Site
Primary Site (femur)
Grade (High/Intermediate vs Low)
Pre-op Chemo
Good response (patients receiving pre-op chemo)*
*Landmark analysis method

p-value
0.435
0.828
0.737
0.361
0.0050
0.192
0.951
0.151
0.525
0.301

Table 5. Log-rank test for relapse-free survival amongst patients with localized disease at
diagnosis. Radiation-induced osteosarcoma was the only clinical or pathologic
characteristic that was significantly associated with RFS.
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Figure 4. Relapse-free survival for patients with localized disease by radiation-induced
subtype. Patients with radiation-induced osteosarcoma demonstrate inferior RFS.
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Clinical and pathologic patient characteristics associated with RFS were analyzed
using a univariate Cox model. Radiation induced osteosarcoma was significantly
associated with poor RFS (HR: 2.85 [1.33-6.12], p=0.007) compared without radiation
induced osteosarcoma (Table 6).
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Factor
Age at diagnosis

No. of
deaths
121

Total
n
215

Univariate analysis
PHR (95% CI)
value
1.01 (1.00, 1.02)
0.133

40
65

89
126

Ref
1.16 (0.80, 1.67)

0.435

98
7

207
8

Ref
2.85 (1.33, 6.12)

0.007

48
57

103
112

Ref
1.01 (0.71, 1.45)

0.951

1
104

6
209

Ref
2.68 (0.66, 10.8)

0.168

2
103

7
208

Ref
1.45 (0.46, 4.56)

0.527

43
59

92
113

Ref
1.21 (0.84, 1.75)

0.302

Sex
Female
Male
Radiation Induced Osteosarcoma
No
Yes
Primary Site (femur vs others)
Others
Femur
Grade (High/Intermediate vs low)
Low
High/ Intermediate
Pre-op Chemo
No
Yes
Good response (patients with pre-op
chemo)*
Yes
No
*Landmark analysis method

Table 6. Relapse-free survival analysis for patients with localized disease (univariate Cox
regression model).
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Amongst patients with localized osteosarcoma, there were 105 deaths during the
follow-up period; 110 patients were alive at the time of analysis. The median follow-up
time was 11.0 years. The estimated overall survival (OS) was 12.0 years (95% CI 7.0320.3). Table 7 shows the log-rank test results for clinical characteristics related to overall
survival. Patients with radiation induced osteosarcoma had inferior OS as compared to
patients without radiation induced osteosarcoma (Figure 5, p=0.0003).
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Factor
Gender
Race
Histologic Subtype
Histologic Subtype (Osteoblastic vs others)
Radiation Induced osteosarcoma
Primary Site
Primary Site (femur vs others)
Grade (High/Intermediate vs Low)
Pre-op Chemo
Good response (patients with Pre-op chemo)*
*Landmark analysis method

p-value
0.615
0.597
0.682
0.726
0.0003
0.162
0.555
0.119
0.574
0.0958

Table 7. Log-rank test for overall survival amongst patients with localized disease at
diagnosis. Radiation-induced osteosarcoma was the only clinical or pathologic
characteristic that was significantly associated with OS. Good response (pathologic tumor
necrosis >90%) showed a trend toward significance.
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Figure 5. Overall survival for patients with localized disease by radiation-induced
subtype. Patients with radiation-induced osteosarcoma demonstrate inferior OS.
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Clinical and pathologic patient characteristics associated with OS amongst
patients with localized osteosarcoma were analyzed using a univariate and multivariate
Cox models. Higher age at diagnosis (HR 1.02 [1.00-1.03], p=0.0063) and radiationassociated osteosarcoma (HR 3.76 [1.74-8.12], p=0.001) were significantly associated
with inferior overall survival in a univariate model; these factors remained significant in
multivariate analysis (all p < 0.03, Table 8). Patients with poor response to pre-operative
chemotherapy showed a trend toward inferior overall survival in a landmark analysis (HR
1.4 [0.94-2.07], p=0.097).
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No. of
deaths

Tot
al

105

215

Female

40

89

Male
Radiation
Induced
osteosarcoma
No

65

126

98

207

Yes
Primary
Site
(femur vs others)
Others

7

8

48

103

Femur

57

112

1

6

104

209

2

7

103

208

43

92

Factor
Age at diagnosis
(years)

Univariate analysis
PHR (95% CI) value
1.02 (1.00,
0.006
1.03)
3

Multivariate analysis
PHR (95% CI)
value
1.01 (1.00,
1.03)
0.0294

Sex

Grade
(High/Intermediat
e vs low)
Low
High/
Intermediate
Pre-op Chemo
No
Yes
Good
response
(patients
with
pre-op chemo)*
Yes

No
59
113
*Landmark analysis method

Ref
1.11 (0.75,
1.64)

0.615

Ref
3.76 (1.74,
8.12)

0.001

Ref
1.10 (0.76,
1.65)

0.556

Ref
4.23 (0.59,
30.4)

0.152

Ref
1.49 (0.37,
6.05)

0.577

Ref
1.40 (0.94,
2.07)

0.097

Ref
3.08 (1.38,
6.86)

0.0061

Table 8. Overall survival analysis for patients with localized disease (univariate and
multivariate Cox regression models).
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Progression-free and overall survival for patients with metastatic osteosarcoma
Patients with primary metastatic disease at the time of diagnosis have inferior
outcomes. Because this is a well-established poor prognostic group, survival outcomes
and biomarkers for patients with metastasis at diagnosis were analyzed separately from
patients with localized osteosarcoma.
Among the 45 patients with primary metastatic disease, 32 (71%) died during the
follow-up period, with a median follow up of 10.6 years. The median overall survival
was 2.47 years (95%CI 1.70-3.51). Patients with poor response to pre-operative
chemotherapy had inferior progression-free survival (HR 2.4 [1.11-5.22]; table 9).
Patients who did not receive preoperative chemotherapy also had inferior PFS (2 patients,
HR 6.14 [1.34- 28.1]). Failure to receive preoperative chemotherapy was associated with
inferior OS (log-rank p=0.0045; Cox HR 6.82 [1.47-31.7]). This likely represents
patients who were too critically ill at the time of presentation to receive chemotherapy
and/or surgery. No other clinical characteristics analyzed were significantly associated
with overall survival amongst patients with primary metastatic disease (Tables 10 and
11).
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Factor
Age at diagnosis

No. of
deaths/
progression

Total
n

Hazard ratio (95%
CI)
1.01 (0.99, 1.03)

Pvalue
0.380

14
22

18
27

Ref
1.02 (0.52, 2.00)

0.945

20
16

26
19

Ref
1.05 (0.54, 2.03)

0.886

12
24

17
28

Ref
1.42 (0.71, 2.85)

0.323

29
2

38
2

Ref
6.14 (1.34, 28.1)

0.019

10
19

16
22

Ref
2.40 (1.11, 5.22)

0.027

sex
Female
Male
Histologic Subtype (Osteoblastic)
Others
Osteoblastic
Primary site (Femur)
Others
Femur
Pre-op Chemo
Yes
No
Good Response (with Pre-op
Chemo)*
Yes
No
*Landmark analysis method

Table 9. Progression-free survival analysis for patients with primary metastatic disease
(univariate Cox regression model).
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Factor
Gender
Race
Histologic Subtype
Histologic Subtype (Osteoblastic vs others)
Primary Site
Primary Site (femur vs others)
Pre-op Chemo
Good response (patients with pre-op Chemo)*
* *Landmark analysis method

p-value
0.595
0.551
0.275
0.669
0.0448
0.444
0.0045
0.554

Table 10. Log-rank test for overall survival amongst patients with metastatic disease at
diagnosis. Failure to receive preoperative chemotherapy was the only factor associated
with OS. Of note, only 2 patients did not receive preoperative chemotherapy.
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Factor

No. of deaths

Total n

32

45

Male

19

27

Female
Subtype

13

18

Others

17

26

Osteoblastic
Primary site (Femur)
Others

15

19

11

17

Femur

21

28

Yes

25

38

No
Good Response (with Preop Chemo)*
Yes

2

2

10

16

No

14

21

Age at diagnosis

HR (95% CI) p-value
1.01
(0.99,
1.03)
0.496

Sex

Histologic
(Osteoblastic)

Ref
1.21 (0.60,
2.46)

0.596

Ref
1.17 (0.57,
2.37)

0.669

Ref
1.33 (0.64,
2.77)

0.445

Ref
6.82 (1.47,
31.7)

0.014

Ref
1.28 (0.57,
2.89)

0.555

Pre-op Chemo

*Landmark analysis method
Table 11. Overall survival analysis for patients with primary metastatic disease
(univariate Cox regression model).
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Expression of HSP27 and LC3 in Osteosarcoma Patient Samples
The osteosarcoma tissue microarray included 394 osteosarcoma tumor specimens
consisting of 116 pre-treatment biopsies, 184 primary resection specimens, and 94
metastatic tumor specimens.

Metastatic specimens included a combination of

synchronous metastasis (26, 28%) and metachronous metastasis (68, 72%). Due to the
fragility of samples following the decalcification and staining process, not all sample
were evaluable for all biomarkers analyzed.

LC3B expression in osteosarcoma patient samples
The percentage of osteosarcoma cells with clearly visible cytoplasmic LC3B+
puncta labeling were quantified, with ≥10% considered positive based upon established
cutoffs in other tumor types.56 LC3B+ expression was significantly higher in resection
specimens and metastasis as compared to pre-treatment biopsies (50% and 67%
respectively vs 34%, p=0.004). Examples of LC3B labeling are shown in Figure 6. The
intensity of cytoplasmic LC3B staining was heterogeneous. A higher proportion of pretreatment biopsy specimens were graded as 0 or negative (66%) as compared to resection
(47%) or metastasis (30%, Table 12).
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A

B

C

Figure 6. Examples of LC3B labeling in osteosarcoma tumor specimens and normal
lung. Punctate labeling (A) as well as granular cytoplasmic labeling (B) in osteosarcoma
tumor cells were considered positive. In normal human lung tissue, pneumocytes are
negative for LC3B whereas macrophages stain positive (C).

Factor

LC3B Expression in Patient Samples
All
Biopsy Resection Metastatic
n (%)
n (%)
n (%)
n (%)

LC3B intensity
None
Weak
Moderate
Strong
LC3B percent (10% as
cutoff)
<10%
≥10%

122 (47)
82 (31)
54 (21)
3 (1)

38 (66)
7 (12)
11 (19)
2 (3)

64 (47)
43 (31)
29 (21)
1 (1)

20 (30)
32 (48)
14 (21)

128 (49)
133 (51)

38 (66)
20 (34)

68 (50)
69 (50)

22 (33)
44 (67)

Table 12. Punctate LC3B expression in osteosarcoma patient samples by IHC. Samples
scored by intensity and percent of tumor cells expressing LC3B+ puncta.
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Paired pre-treatment biopsy and post-treatment resection specimens were
available for LC3B puncta evaluation in 18 patients, including 9 LCB+ at biopsy and 9
LC3B negative prior to treatment. Five of 9 patients (56%) who were initially negative
for LC3B puncta were positive for the autophagy marker at the time of resection
following chemotherapy. Conversely, 8/9 patients (89%) who were positive prior to
chemotherapy remained positive at resection (Table 13). These findings suggest that the
presence of LC3B puncta at resection may represent chemotherapy-induced autophagy in
a subset of patients. Similarly, amongst 6 patients with negative LC3B expression in pretreatment samples, 3 subsequently had LC3B+ puncta in metachronous metastatic
specimens and 3 remained negative. Resection-metastasis pairs were available in 26
patients. Amongst 13 who were negative for LC3B expression at resection, 9 (69%)
demonstrated LC3B+ puncta in metachronous metastatic specimens (Table 13).
Differences in LC3B expression amongst the pairs were not statistically significant,
however this may be due to the small sample size.
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LC3B+ (10% cutoff) in paired biopsy-resection specimens
Resection
McNemar's test p-value
Biopsy
≥10%
<10%
0.103
<10%
4
5
≥10%
1
8
LC3B+ (10% cutoff) in paired biopsy-metastasis specimens
Metastasis
McNemar's test p-value
Biopsy
≥10%
<10%
0.0833
<10%
3
3
≥10%
0
2
LC3B+ (10% cutoff) in paired resection-metastasis specimens
Metastasis
McNemar's test p-value
Resection
≥10%
<10%
0.166
<10%
4
9
≥10%
4
9
Table 13. LC3B puncta in paired osteosarcoma tumor specimens.
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HSP27 and pHSP27 expression in osteosarcoma patient samples
The percent and intensity of HSP27 expression was variable, with some tumor
having strong diffuse expression in tumor cells and others having no appreciable HSP27
expression (Figure 7).

A

B

Figure 7. Representative expression of HSP27 in osteosarcoma tumor specimens.
Expression was variable, with some tumor having strong, diffuse staining (A) and others
showing no expression (B).
The percentage of osteosarcoma cells with HSP27 staining was quantified, with ≥10%
considered positive. Two-thirds of all tumor specimens analyzed were scored as positive
for HSP27 expression. The proportion of HSP27+ tumors was higher in pre-treatment
biopsy (85%) and metastasis specimens (79%) as compared to resection (52%), although
this was not statistically significant. The intensity of HSP27 staining was variable across
all groups. There was no significant correlation between HSP27 expression and LC3B
expression (Spearman correlation 0.006, p=0.945). HSP27 expression is summarized in
table 14.
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Factor

HSP27 Expression in Patient Samples
All
Biopsy Resection Metastatic
n (%)
n (%)
n (%)
n (%)

HSP27 intensity
None
Weak
Moderate
Strong

41 (16)
144 (57)
38 (15)
29 (12)

9 (16)
28 (48)
16 (28)
5 (9)

28 (21)
74 (56)
13 (10)
16 (12)

4 (6)
42 (67)
9 (14)
8 (13)

HSP27 percent (10% as
cutoff)
<10%
≥10%

85 (34)
168 (66)

9 (15)
50 (85)

63 (48)
68 (52)

13 (21)
50 (79)

Table 14. Heat shock protein 27 (HSP27) expression in osteosarcoma patient samples by
IHC. Samples scored by intensity and percent of tumor cells expressing HSP27.

49

The percentage and intensity of osteosarcoma cells with phosphorylated HSP27
(pHSP27 S78/S82) staining was quantified. The expression of pHSP27 was very limited
(representative staining shown in figure 8) at all time points, with only 16% of all
specimens tested showing any staining and 8% considered positive (pHSP27 >10%; table
15). This likely reflects a degradation of phosphoproteins in the acquisition and
processing (decalcification) of bone tumor specimens, rather than a true lack of pHSP27.
Due to the limited labeling, no significant inferences could be made regarding the
prognostic significance of pHSP27 or its correlation with other biomarkers of interest.
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Figure 8. Representative expression of pHSP27 in osteosarcoma tumor specimens.
pHSP27 Expression in Patient Samples
Factor
All
Biopsy Resection Metastatic
n (%)
n (%)
n (%)
n (%)
pHSP27 intensity
None
241 (84)
44 (77)
133 (88)
64 (82)
Weak
39 (14)
11 (19)
16 (11)
12 (15)
Moderate
4 (1)
2 (4)
2 (1)
Strong
3 (1)
1 (1)
2 (3)
pHSP27 percent (10% as
cutoff)
<10%
264 (92)
44 (77)
143 (94)
77 (99)
≥10%
23 (8)
13 (23)
9 (6)
1 (1)
Table 15. Phosphorylated heat shock protein 27 (pHSP27 S78/S82) expression in
osteosarcoma patient samples by IHC. Samples scored by intensity and percent of tumor
cells expressing HSP27.
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Prognostic Significance of HSP27 Expression and LC3B Puncta in Osteosarcoma
Patients

LC3B as a prognostic biomarker in localized osteosarcoma
The presence of LC3B puncta labeling in pre-treatment specimens was not
associated with relapse-free or overall survival. Localized osteosarcoma patients with
LC3B puncta staining present at resection (which was found in 50% of cases) had
superior overall survival (Figure 9, p=0.031).
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Figure 9. Overall survival for localized osteosarcoma patients stratified according to
cytoplasmic LC3B puncta expression at resection (>10% positive, <10% negative)
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The lack of LCB puncta labeling at resection was associated with inferior relapsefree survival in univariate analysis (HR 1.81 [1.10-2.98], p=0.019) but only maintained
borderline significance when adjusted for radiation-induced osteosarcoma in the
multivariate model (HR 1.65 [0.99-2.75], p=0.053; table 16). This lack of LC3B at
resection following chemotherapy was significantly associated with inferior overall
survival in both the univariate (HR 1.78 [1.05-3.03], p=0.034) and multivariate analysis
(HR 1.75 [1.01-3.04], p=0.045) when adjusted for age and radiation-induced
osteosarcoma (Table 17). A median cutpoint was also explored and found to yield
prognostic significance: patients with LC3B ≤ median at resection had inferior relapse
free (lor rank p=0.004) and overall survival (log rank p=0.0068). Taken together, our
findings suggest that presence of LC3B puncta can be considered an independent
prognostic biomarker of improved survival following preoperative chemotherapy.
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Univariate
No. of
deaths

Tota
ln

HR (95% CI)

None

10

22

Ref

Weak, moderate, strong

52

81

1.76 (0.89, 3.49)

None, weak

43

78

Ref

Moderate, strong

19

25

1.70 (0.98, 2.96)

≤ median

28

55

Ref

> median

34

48

1.74 (1.04, 2.91)

<10%

22

47

Ref

≥10%

40

56

1.92 (1.13, 3.28)

None

63

103

Ref

Weak, moderate, strong

11

17

1.21 (0.63, 2.29)

≤ median

63

103

Ref

> median

11

17

1.21 (0.63, 2.29)

<10%

68

111

Ref

≥10%

6

9

1.25 (0.54, 2.89)

Weak, moderate, strong

28

56

Ref

None

38

51

1.82 (1.11, 2.97)

Moderate, strong

13

27

Ref

None, weak

53

80

1.32 (0.72, 2.43)

> median

22

48

Ref

≤ median

44

59

2.09 (1.25, 3.50)

≥10%

26

53

Ref

<10%

40

54

1.81 (1.10, 2.98)

Factor

Multivariate*
P-value

HR (95% CI)

P-value

HSP27 intensity
Ref
0.107

1.68 (0.84, 3.33)

0.141

HSP27 intensity
Ref
0.0598

1.86 (1.06, 3.26)

0.0307

HSP27 percent (median)
Ref
0.0336

1.57 (0.93, 2.66)

0.016

1.76 (1.03, 3.03)

0.0912

HSP27 percent (10%)
Ref
0.0398

pHSP27 intensity
Ref
0.568

1.28 (0.67, 2.44)

0.456

pHSP27 percent (median)
Ref
0.568

1.28 (0.67, 2.44)

0.456

pHSP27 percent (10%)
Ref
0.6

1.30 (0.56, 3.01)

0.538

LC3 intensity
Ref
0.0174

1.65 (1.00, 2.73)

0.374

1.24 (0.67, 2.29)

0.0525

LC3 intensity
Ref
0.488

LC3 percent (median)
Ref
0.0051

1.93 (1.14, 3.25)

0.0142

LC3 percent (10%)
Ref
0.0192

1.65 (0.99, 2.75)

0.0527

*Adjusting for radiation induced osteosarcoma

Table 16. Univariate and multivariate analyses (Cox regression) for biomarkers at
resection associated with RFS.
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Univariate
No. of
deaths

Total n

HR (95% CI)

7

22

Ref

46

81

2.11 (0.95, 4.73)

None, weak

35

78

Ref

Moderate, strong
HSP27
percent
(median)

18

25

2.02 (1.14, 3.59)

≤ median

23

55

Ref

> median

30

48

1.72 (0.99, 2.98)

<10%

18

47

Ref

≥10%

35

56

2.00 (1.12, 3.56)

None
Weak, moderate,
strong
pHSP27
percent
(median)

54

103

Ref

10

17

1.33 (0.67, 2.61)

≤ median

54

103

Ref

> median

10

17

1.33 (0.67, 2.61)

<10%

59

111

Ref

≥10%

5

9

1.09 (0.44, 2.71)

LC3 intensity
Weak, moderate,
strong

24

56

Ref

None

34

51

1.78 (1.05, 3.00)

Moderate, strong

11

27

Ref

None, weak

47

80

1.34 (0.69, 2.60)

> median

18

48

Ref

≤ median

40

59

2.12 (1.21, 3.70)

22

53

Ref

Factor

Multivariate*
Pvalue

HR (95% CI)

Pvalue

HSP27 intensity
None
Weak, moderate,
strong

Ref
0.0683

2.13 (0.95, 4.78)

0.0661

HSP27 intensity
Ref
0.0166

2.27 (1.26, 4.11)

0.0541

1.53 (0.87, 2.68)

0.0065

Ref
0.137

HSP27 percent (10%)
Ref
0.0197

1.85 (1.03, 3.33)

0.0395

pHSP27 intensity
Ref
0.413

1.32 (0.67, 2.63)

0.423

Ref
0.413

1.32 (0.67, 2.63)

0.860

1.14 (0.46, 2.85)

0.423

pHSP27 percent (10%)
Ref
0.778

Ref
0.0315

1.69 (0.99, 2.90)

0.0556

LC3 intensity
Ref
0.382

1.34 (0.69, 2.61)

0.395

LC3 percent (median)
Ref
0.0082

2.15 (1.21, 3.81)

0.0337

1.75 (1.01, 3.04)

0.0089

LC3 percent (10%)
≥10%

<10%
36
54
1.78 (1.05, 3.03)
*Adjusting for age and radiation induced osteosarcoma

Ref
0.0448

Table 17. Univariate and multivariate analyses (Cox regression) for biomarkers at
resection associated with OS.
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HSP27 as a prognostic biomarker in localized osteosarcoma
The majority of osteosarcoma specimens were scored as HSP27+ in pre-treatment
samples. While HSP27+ in pre-treatment samples was not significant in univariate
analysis for relapse free survival or overall survival, it was associated with inferior
relapse-free survival (HR: 12.5 [1.34-116], p=0.027) and overall survival (HR: 26.7
[1.47-484], p=0.0263) in multivariate analysis (tables 18 and 19, respectively). At
resection, patients with HSP27+ osteosarcoma had inferior overall survival (Figure 10,
p=0.017). HSP27+ in resection specimens was associated with inferior relapse-free
survival in both the univariate (HR 1.92 [1.13-3.28], p=0.016) and multivariate models
(HR 1.76 [1.03-3.03], p=0.039; table 16) as well as worse overall survival (univariate HR
2.00 [1.12-3.56], p=0.0197, multivariate HR: 1.85 [1.03-3.33], p=0.039; table 17). A
median cutpoint and stratification by intensity (none/weak vs. moderate/strong) was also
explored and showed a similar trend with high expression of HSP27 associated with
inferior outcomes. However neither measure was statistically significant in both the
univariate and multivariate models for both RFS and OS (at resection summarized in
tables 16 and 17; pre-treatment specimens in tables 18 and 19).
Phosphorylated HSP27 was evaluated as a potential biomarker based upon the
initial hypothesis. There were no significant associations between pHSP27 expression
based upon percent staining, median cutoff, or intensity prior to treatment or at resection
in relation to either RFS or OS. Further, there was no correlation between pHSP27
positivity (any criteria) and total HSP27 nor LC3B.
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Univariate
Factor

No. of
deaths

Total
n

HR (95% CI)

2

8

Ref

18

41

2.41 (0.55, 10.6)

Multivariate*
P-value

HR (95% CI)

P-value

HSP27 intensity
None
Weak, moderate,
strong

Ref
0.243

11.5 (1.27, 105)

0.119

2.60 (1.01, 6.73)

0.0299

HSP27 intensity
None, weak

10

30

Ref

Moderate, strong
HSP27
percent
(median)

10

19

2.01 (0.84, 4.85)

≤ median

11

27

Ref

> median

10

23

1.12 (0.47, 2.64)

<10%

2

8

Ref

≥10%

19

42

2.48 (0.57, 10.8)

pHSP27 intensity
Weak, moderate,
strong

4

12

Ref

None
percent

15

36

1.29 (0.43, 3.88)

> median

4

12

Ref

≤ median

15

36

1.29 (0.43, 3.88)

Ref
0.0487

Ref
0.798

1.35 (0.55, 3.32)

0.512

HSP27 percent (10%)

pHSP27
(median)

Ref
0.226

12.5 (1.34, 116)

0.0265

Ref
0.655

1.16 (0.38, 3.53)

0.801

Ref
0.655

1.16 (0.38, 3.53)

0.655

1.16 (0.38, 3.53)

0.801

pHSP27 percent (10%)
≥10%

4

12

Ref

<10%

15

36

1.29 (0.43, 3.88)

LC3 intensity
Weak, moderate,
strong

4

16

Ref

None

13

34

1.62 (0.53, 4.99)

Moderate, strong

2

10

Ref

None, weak

15

40

2.03 (0.46, 8.89)

> median

4

16

Ref

≤ median

13

34

1.62 (0.53, 4.99)

4

16

Ref

Ref
0.801

Ref
0.399

1.50 (0.48, 4.67)

0.483

LC3 intensity
Ref
0.35

1.90 (0.43, 8.39)

0.398

LC3 percent (median)
Ref
0.399

1.50 (0.48, 4.67)

0.483

LC3 percent (10%)
≥10%

<10%
13
34
1.62 (0.53, 4.99)
*Adjusting for radiation induced osteosarcoma

Ref
0.399

1.50 (0.48, 4.67)

0.483

Table 18. Univariate and multivariate analyses (Cox regression) for biomarkers assessed
in pre-treatment biopsy specimens associated with RFS.
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Univariate
No. of
deaths

Total
n

HR (95% CI)

None

1

8

Ref

Weak, moderate, strong

15

41

3.68 (0.49, 28.0)

None, weak

8

30

Ref

Moderate, strong
HSP27 percent (median
as cutoff)

8

19

1.90 (0.71, 5.09)

≤ median

8

27

Ref

> median

9

23

1.52 (0.59, 3.97)

Factor

Multivariate*
P-value

HR (95% CI)

Pvalue

HSP27 intensity
Ref
0.207

23.1 (1.34, 397)

0.0306

HSP27 intensity
Ref
0.201

2.39 (0.84, 7.10)

0.117

Ref
0.388

1.85 (0.68, 5.01)

0.198

26.7 (1.47, 484)

0.227

HSP27 percent (10%)
<10%

1

8

Ref

≥10%

16

42

3.78 (0.50, 28.6)

Weak, moderate, strong

3

12

Ref

None
pHSP27
percent
(median as cutoff)

11

36

1.18 (0.33, 4.27)

> median

3

12

Ref

≤ median

11

36

1.18 (0.33, 4.27)

Ref
0.0263

pHSP27 intensity
Ref
0.796

1.20 (0.32, 4.49)

0.787

Ref
0.796

1.20 (0.32, 4.49)

0.796

1.20 (0.32, 4.49)

0.787

pHSP27 percent (10%)
≥10%

3

12

Ref

<10%

11

36

1.18 (0.33, 4.27)

Weak, moderate, strong

3

16

Ref

None

9

34

1.38 (0.37, 5.12)

Moderate, strong

2

10

Ref

None, weak

10

40

1.10 (0.24, 5.06)

> median

3

16

Ref

≤ median

9

34

1.38 (0.37, 5.12)

3

16

Ref

Ref
0.787

LC3 intensity
Ref
0.631

1.40 (0.34, 5.82)

0.646

LC3 intensity
Ref
0.905

1.02 (0.21, 4.84)

0.631

1.40 (0.34, 5.82)

0.983

LC3 percent (median)
Ref
0.646

LC3 percent (10%)
≥10%

<10%
9
34
1.38 (0.37, 5.12)
*Adjusting for age and radiation induced osteosarcoma

Ref
0.631

1.40 (0.34, 5.82)

0.646

Table 19. Univariate and multivariate analyses (Cox regression) for biomarkers assessed
in pre-treatment biopsy specimens associated with OS.
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Figure 10. Overall survival for localized osteosarcoma patients stratified according to
HSP27 expression at resection (>10% positive, <10% negative)
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Combined analysis of LC3B puncta and HSP27 was evaluated for further risk
stratification amongst patients with localized disease. In pre-treatment biopsy samples
from 32 evaluable patients, the combination of HSP27+/LC3B- was associated with a
trend towards inferior survival (log rank p=0.087). Ninety-two patients with localized
disease had resection specimens with HSP27 and LC3B biomarker data available for
analysis. Patients with HSP27-/LC3B+ tumors had significantly improved overall
survival as compared to all others (p=0.012, Figure 11). This was stratified into 4 groups
with HSP27-/LC3B+ having favorable outcomes, HSP27+/LC3B+ or HSP27-/LC3Bwith intermediate risk, and HSP27+/LC3B- having the worst overall survival (p=0.018,
Figure 12).
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Figure 11. Overall survival for localized osteosarcoma patients combined biomarker
analysis at resection, HSP27-/LC3B+ vs all others. HSP27-/LC3B+ patients have
significantly improved OS as compared to all others.
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Figure 12. Overall survival for localized osteosarcoma patients stratified by combined
biomarker analysis at resection yields 3 risk groups: good risk (HSP27-/LC3B+),
intermediate risk (HSP27+/LC3B+ or HSP27-/LC3B-), or poor risk (HSP27+/LC3B-).
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Pathologic treatment response assessed by percent tumor necrosis following
neoadjuvant chemotherapy is the most well established prognostic marker in patients
with localized osteosarcoma. Neither LC3B percentage nor HSP27 percentage expression
in pre-treatment specimens correlated with percent tumor necrosis following neoadjuvant
chemotherapy (Spearman correlation -0.12, p=0.384 and -0.067, p=0.655 respectively).
Further, there was no association between LC3B+ puncta in pre-treatment samples and a
good pathologic response to chemotherapy (p=0.391) nor between HSP27+ and good
pathologic response (p=1.00, Table 20). Additionally, no significant association was seen
between either marker at resection and a good response to therapy (data not shown). In a
subset of localized OS patients with poor response to therapy (tumor necrosis <90%), the
lack of LC3B puncta was associated with a trend toward inferior overall survival (HR:
1.87 [0.96-3.64], p=0.0665; Figure 13).
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Poor
response
n (Column
%)

Factor

Good
response
n (Column
%)

Poor
response
n (row
%)

Good
response
n (row
%)

P-value

1a

HSP27 intensity
None

3 (14)

4 (13)

3 (43)

4 (57)

Weak, moderate, strong

19 (86)

26 (87)

19 (42)

26 (58)
0.756b

HSP27 intensity
None

13 (59)

19 (63)

13 (41)

19 (59)

Weak, moderate, strong

9 (41)

11 (37)

9 (45)

11 (55)
0.758b

HSP27 percent (median)
≤ median

13 (59)

17 (55)

13 (43)

17 (57)

> median

9 (41)

14 (45)

9 (39)

14 (61)
1a

HSP27 percent (10%)
<10%

3 (14)

4 (13)

3 (43)

4 (57)

≥10%

19 (86)

27 (87)

19 (41)

27 (59)
0.391b

LC3 intensity
None

16 (62)

21 (72)

16 (43)

21 (57)

Weak, moderate, strong

10 (38)

8 (28)

10 (56)

8 (44)
0.831b

LC3 intensity
None, weak

20 (77)

23 (79)

20 (47)

23 (53)

Moderate, strong

6 (23)

6 (21)

6 (50)

6 (50)
0.391b

LC3 percent (median)
≤ median

16 (62)

21 (72)

16 (43)

21 (57)

> median

10 (38)

8 (28)

10 (56)

8 (44)
0.391b

LC3 percent (10%)
<10%

16 (62)

21 (72)

16 (43)

21 (57)

≥10%
10 (38)
a: Fisher’s exact test, b: Chi-square test

8 (28)

10 (56)

8 (44)

Table 20. Association between pre-treatment biomarker expression and pathologic
treatment response to preoperative chemotherapy. Good pathologic response is defined as
≥ 90% tumor necrosis at the time of resection.
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Figure 13. Overall survival for localized osteosarcoma patients with poor response
pathologic response to preoperative chemotherapy stratified according LC3B+ at
resection. Amongst poor responders, presence of LC3B+ puncta is associated with a
trend towards improved OS.
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HSP27 and LC3B as prognostic biomarkers in primary metastatic osteosarcoma
The prognostic significance of HSP27 and LC3B in patients with primary
metastatic disease was evaluated at the time of diagnosis (pre-treatment) and at resection
for patients who underwent resection of the primary tumor. Due to the limited number of
samples, no meaningful inferences could be made based upon pretreatment expression of
either marker. For example, amongst 9 patients with metastatic osteosarcoma who had
evaluable pretreatment samples, 8/9 (89%) were positive for HSP27 (>10% expression).
Similarly, at resection, neither LC3B+ (any criteria) nor HSP27+ (any criteria) was
associated with either PFS or OS.
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The Dual Role of Chemotherapy-induced Autophagy in Osteosarcoma Cells
Several studies have evaluated the presence and significance of chemotherapyinduced autophagy in osteosarcoma cell lines and to a lesser extent, mouse xenograft
models.64 The majority of these works have focused on autophagy as a mechanism of
chemoresistance and therefore explore autophagy inhibition as a means to enhance
chemotherapeutic efficacy. In prior studies from our lab, we have shown that
chemotherapy-induced autophagy in osteosarcoma can have a dual role, either
cytoprotective or cytotoxic, following treatment with 9-nitrocamptothecin (9-NC)72 or
gemcitabine (GCB).73 Further, in a recent paper from our group, we showed that the posttreatment expression of pHSP27 correlated with the role of autophagy (and treatment
effect of autophagy inhibition with hydroxychloroquine [HCQ]) in vitro for both 9-NC
and GCB.
Both cisplatin and doxorubicin have previously been shown to induce autophagy
in multiple osteosarcoma cell lines including MG-63, SaOS-2, and U-2 OS amongst
others. In these studies, standard MAP chemotherapy resulted in chemoresistance, and
the inhibition of autophagy (either pharmacologic or by shRNA knockdown of key
autophagy genes) resulted in enhanced chemosensitivity.65-67, 70, 101 To our knowledge,
however, no preclinical models or in vitro experiments have shown a cytotoxic role for
autophagy following doxorubin or cisplatin. Based upon our preliminary data with 9-NC
and GCB in osteosarcoma cell lines in conjunction with the clinical biomarker data
suggesting a favorable role for autophagy following standard chemotherapy, we sought to
determine whether standard chemotherapy can result in either cytototxic or cytoprotective
autophagy in osteosarcoma cell lines and determine whether pHSP27 expression
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correlates with the cytoprotective function of chemotherapy-induced autophagy following
treatment with doxorubicin or cisplatin.
Doxorubicin and cisplatin induce autophagy in LM7 and CCH-OS-D
Changes in key autophagy proteins were evaluated by Western blot to confirm the
induction of autophagy following treatment with either doxorubicin or cisplatin
treatment. LC3 and p62 are common markers of autophagy and autophagic flux. Upon
induction of autophagy, LC3I is conjugated to phosphatidylenthanolamine to form LC3II
which is then recruited to the autophagosomal membrane and subsequently degraded in
the autolysosome. This process results in an increase in the LC3II/LC3I ratio that is
indicative of activation or induction of autophagy. p62, also known as SQSTM1, is often
used as a protein marker of autophagic flux. When autophagy is induced, p62 is
incorporated into the autophagosome and is degraded. Thus the combination of an
increased LC3II/LC3I ratio and decrement in p62 are suggestive of an increase in
autophagy, and more specifically autophagic flux.57 Finally, the lysosomal inhibitor
hydroxychloroquine blocks the late-stages of autophagy resulting in an increase in
LC3II/LC3I.
Initially, LM7 cells were treated with either doxorubicin (DOX, 0.2 ug/mL),
cisplatin (CDDP, 20uM), hydroxychloroquine alone (HCQ, 20 uM), or the combination
of DOX+HCQ, or CDDP+HCQ and collected at 48 hours post-treatment. For the
combination, cells were pretreated with HCQ for 20 minutes prior to the addition of
DOX. Evaluation of LC3 showed a modest increase in the LC3II/LC3I ratio for DOX and
CDDP alone, and as expected, a significant increase LC3II accumulation in all groups
containing HCQ (Figure 14).
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Figure 14. DOXO and CDDP increase LC3II expression in LM7 cells. Osteosarcoma
cells were grown until 70-80% confluent and treated with HCQ (20 uM), DOXO (0.2
ug/mL), HCQ+DOXO (pretreatment with HCQ for 20 minutes, followed by DOXO),
CDDP (20 uM), or HCQ+CDDP (pretreatment with HCQ for 20 minutes, followed by
CDDP). Cells were collected and lysed using RIPA buffer. Equal amounts of total protein
were resolved in SDS-PAGE, transferred to a nitrocellulose membrane and blotted using
specific antibodies for LC3. Beta-actin is used as a loading control. Western blot analysis
and densitometry show increase in LC3II/LC3I ratio following treatment with DOXO or
CDDP compared to untreated control consistent with induction of autophagy. LC3II
accumulation is seen in all HCQ containing conditions, consistent with late-autophagy
inhibition. p62 is needed to confirm the presence of autophagic flux, but was not able to
be performed.
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Next, this experiment was repeated for LM7 cells with DOX alone (0.2ug/mL) for
48 and 72 hours. Under these conditions, induction of autophagy was not readily apparent
(qualitative expression of p62 and LC3 shown in figure 15). While the HCQ either alone
or in combination with DOX resulted in an increase accumulation of LC3II, DOX alone
did not significantly alter either p62 or LC3 expression in comparison to untreated
controls.
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Figure 15. Autophagy induction is not apparent with standard doses of DOXO at 48 and
72 hours in LM7 cells. Osteosarcoma cells were grown until 70-80% confluent and
treated with HCQ (20 uM), DOXO (0.2 ug/mL), HCQ+DOXO (pretreatment with HCQ
for 20 minutes, followed by DOXO). Cells were collected and lysed using RIPA buffer.
Equal amounts of total protein were resolved in SDS-PAGE, transferred to a
nitrocellulose membrane and blotted using specific antibodies for LC3 and p62. Betaactin is used as a loading control. Qualitative changes in p62 and LC3II/LC3I were not
consistent with autophagy induction, where a decrement in p62 and increase in LC3II
would be expected. HCQ containing conditions result in increased LC3II accumulation.
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Subsequently, LM7 cells were treated with escalating doses of DOX (0.2-0.8
ug/mL) and collected at 24, 48, and 72 hours post-treatment. LC3I to LC3II conversion
was assessed; DOX+HCQ was used as a positive control. This demonstrated a relative
increase in the LC3II/LC3I ratio with increasing doses and longer drug exposure (Figure
16).
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Figure 16. Autophagy induction with DOXO increase with dose and time in LM7 cells.
Osteosarcoma cells were grown until 70-80% confluent and treated with increasing doses
of DOXO (0.2 – 0.8 ug/mL) for 24, 48, and 72 hours. DOXO+HCQ was used as a
positive control. Cells were collected and lysed using RIPA buffer. Equal amounts of
total protein were resolved in SDS-PAGE, transferred to a nitrocellulose membrane and
blotted using specific antibodies for LC3. Beta-actin is used as a loading control. Western
blot analysis and densitometry show increase in LC3II/LC3I ratio at later time points and
higher doses consistent with induction of autophagy. LC3II accumulation is seen in
DOX+HCQ consistent with late-autophagy inhibition.
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Our prior experience with LM7 has shown this cell line to be relatively
chemoresistant to multiple chemotherapies, having higher IC50 concentrations as
compared to other human and murine osteosarcoma cell lines. We therefore repeated the
Western blots for LM7 cells treated at higher doses (DOX 1ug/mL and CDDP 40uM) for
48 and 72 hours. DOX resulted in an increase in the LC3II/I ratio at both 48 and 72 hours
but without a concomitant decrease in p62 (Figure 17). CDDP treatment resulted in an
increase in LC3II/I and a decrement in p62 at 48 but not 72 hours (Figure 18). Overall,
these finding suggest that both DOX and CDDP can induce autophagy in LM7 cells,
however the optimal dose and time point for maximal autophaguc flux was not clearly
identified.
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Figure 17. DOXO induces autophagy in LM7 cells. Osteosarcoma cells were grown until
70-80% confluent and treated DOXO (1 ug/mL), HCQ (20 uM), HCQ+DOXO
(pretreatment with HCQ for 20 minutes, followed by DOXO) and collected at 48 and 72
hours. Cells were collected and lysed using RIPA buffer. Equal amounts of total protein
were resolved in SDS-PAGE, transferred to a nitrocellulose membrane and blotted using
specific antibodies for LC3 and p62. Actin is used as a loading control. Western blot
analysis and densitometry show increase in LC3II/LC3I ratio with DOX treatment at 48
and 72 hours compared to untreated controls; DOX did not result in a decrease in p62.
Note, densitometry values were normalized to untreated cells at each respective time
point.
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Figure 18. CDDP induces autophagy in LM7 cells. Osteosarcoma cells were grown until
70-80% confluent and treated CDDP (40 uM), HCQ (20 uM), HCQ+CDDP (pretreatment
with HCQ for 20 minutes, followed by CDDP) and collected at 48 and 72 hours. Cells
were collected and lysed using RIPA buffer. Equal amounts of total protein were resolved
in SDS-PAGE, transferred to a nitrocellulose membrane and blotted using specific
antibodies for LC3 and p62. Actin is used as a loading control. Western blot analysis and
densitometry show increase in LC3II/LC3I ratio and decrease in p62 with CDDP
treatment at 48 as compared to untreated controls consistent with induction of autophagy.
Note, densitometry values were normalized to untreated cells at each respective time
point.
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The results for CCH-OS-D cells were more apparent. CCH-OS-D cells were
treated with either doxorubicin (DOX, 0.2 ug/mL) or cisplatin (CDDP, 20 uM) for 48
hours. GCB treatment was used as a positive control. All treatment groups resulted in an
increase in the LC3II/LC3I ratio and decrement in p62 relative to untreated cells
consistent with induction of autophagy (Figure 19).
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Figure 19. DOXO and CDDP induce autophagy in CCH-OS-D cells. Osteosarcoma cells
were grown until confluent and treated with GCB (1 uM), DOXO (0.2 ug/mL), or CDDP
(20 uM) for 48 hours. Cells were collected and lysed using RIPA buffer. Equal amounts
of total protein were resolved in SDS-PAGE, transferred to a nitrocellulose membrane
and blotted using specific antibodies for LC3 and p62. GAPDH is used as a loading
control. Western blot analysis and densitometry show increase in LC3II/LC3I ratio and
decrease in p62 following treatment with GCB, DOXO, or CDDP compared to untreated
controls consistent with induction of autophagy.
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While autophagy induction was evidenced by changes in autophagy proteins for
CCH-OS-D cells treated with either DOX or CDDP, autophagy induction in LM7 cells as
evaluated by Western blot was only modest at best. Autophagy induction appeared to be
greater at later time points and higher doses of DOX in LM7, however additional studies
are needed to validate these findings and optimize conditions for chemotherapy-induced
autophagy with DOX in LM7 cells. We have previously correlated the findings of
Western blot analysis for autophagy induction in LM7 and CCH-OS-D cell lines treated
with GCB and 9-NC by both acridine orange staining for AVOs and electron microscopy.
These additional assays would allow further evaluation of chemotherapy-induced
autophagy in both cell lines following DOX or CDDP and may validate the findings on
Western blot analysis.

Chemotherapy-induced authophagy serves a dual role in osteosarcoma cells treated with
doxorubicin or cisplatin
The effect of autophagy inhibition can give insights into the role of
chemotherapy-induced

autophagy.

When

chemotherapy

induces

cytoprotective

autophagy and chemoresistance, the addition of autophagy inhibition to chemotherapy
results in increased chemosensitivity and decreased cell viability. Conversely, if
autophagy serves a cytotoxic role and is a mechanism of cell death, blocking autophagy
in addition to chemotherapy is expected to result in increased cell viability. To determine
the role of chemotherapy-induced autophagy in LM7 and CCH-OS-D treated with DOX
and CDDP as either cytoprotective or cytotoxic, viability studies were completed using
chemotherapy alone or in combination with the autophagy inhibitor HCQ.
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LM7 and CCH-OS-D cells were treated with HCQ, DOX alone, CDDP alone, or
combination DOX+HCQ pretreatment or CDDP+HCQ pretreatment and collected at 48
and 72 hours. Viability was assessed using trypan blue exclusion via ViCell and
compared to untreated controls at each time point. All conditions were conducted with 3
replicates and experiments were repeated 3 times. Combining HCQ with either DOX (0.2
ug/mL) or CDDP (20 uM) resulted in a trend towards decreased cell viability for LM7
(Figures 20 and 21, respectively). While this effect was not statistically significant, this
may be in part due to inadequate autophagy induction at the specified dose and time point
of analysis.
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Figure 20. Pharmacologic inhibition of autophagy prior to DOX results in a trend
towards increased chemosensitivity in LM7 cells. Cells were treated with HCQ (20 uM),
DOX (0.2 ug/mL), or pretreated with HCQ for 20 minutes prior to DOX treatment for 48
and 72 hours. Cell viability was measured by trypan blue exclusion assay.
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Figure 21. Pharmacologic inhibition of autophagy prior to CDDP results in a trend
towards increased chemosensitivity in LM7 cells. Cells were treated with HCQ (20 uM),
CDDP (20 uM), or pretreated with HCQ for 20 minutes prior to CDDP treatment for 24,
48, and 72 hours. Cell viability was measured by trypan blue exclusion assay.
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Viability studies in LM7 were repeated with higher doses of DOX (1 ug/mL) and
CDDP (40 uM) alone or in combination with HCQ for 48 and 72 hours. There were no
significant differences in viability at 48 hours amongst the treatment groups (data not
shown). However, at 72 hours combining HCQ with DOX resulted in a trend toward
decreased viability (Figure 22, DOX vs DOX+HCQ p=0.094); combining HCQ with
CDDP also decreased viability (Figure 23, CDDP vs CDDP+HCQ p=0.022). These
findings support a cytoprotective role for autophagy in LM7 cells treated with DOX or
CDDP.
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Figure 22. Pharmacologic inhibition of autophagy prior to higher doses of DOX results
in a trend towards increased chemosensitivity in LM7 cells at 72 hours. Cells were
treated with hydroxychloroquine (CQ), DOX (1ug/mL), or pretreated with CQ for 20
minutes prior to DOX treatment for 72 hours. Cell viability was measured by trypan blue
exclusion assay. There was no difference in viability between untreated controls and
HCQ alone. Pretreatment with HCQ prior to DOX resulted in a trend towards decreased
viability as compared to DOX alone (p=0.094).
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Figure 23. Pharmacologic inhibition of autophagy prior to higher doses of CDDP results
in increased chemosensitivity in LM7 cells. Cells were treated with hydroxychloroquine
(CQ), CDDP (40 uM), or pretreated with HCQ for 20 minutes prior to CDDP treatment
for 72 hours. Cell viability was measured by trypan blue exclusion assay. There was no
difference in viability between untreated controls and HCQ alone. Pretreatment with
HCQ prior to CDDP resulted in decreased cell viability as compared to CDDP alone
(p=0.022).
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Conversely, the pretreatment with HCQ prior to DOX in CCH-OS-D resulted in
increased cell viability at 48 and 72 hours (Figure 24). Combining in HCQ with CDDP in
CCHOSD cells resulted in no change in viability (Figure 25). Notably, treatment with
CDDP alone resulted in significant cytotoxicity at both 48 and 72 hours in CCH-OS-D
cells which may have limited the apparent effect adding the autophagy inhibitor HCQ.
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Figure 24. Pharmacologic inhibition of autophagy prior to DOX results in decreased
chemosensitivity in CCH-OS-D cells. Cells were treated with HCQ (20 uM), DOX (0.2
ug/mL), or pretreated with HCQ for 20 minutes prior to DOX treatment for 48 and 72
hours. Cell viability was measured by trypan blue exclusion assay. Pretreatment with
HCQ prior to DOX resulted in increased cell viability as compared to DOX alone
(p<0.001).
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Figure 25. Pharmacologic inhibition of autophagy prior to CDDP does not alter
chemosensitivity in CCH-OS-D cells. Cells were treated with HCQ (20 uM), CDDP (20
uM), or pretreated with HCQ for 20 minutes prior to CDDP treatment for 48 and 72
hours. Cell viability was measured by trypan blue exclusion assay. CDDP alone
significantly decreased viability at both 48 and 72 hours; pretreatment with HCQ did not
change viability at either time point.
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Taken together, these findings support a dual role for chemotherapy-induced
autophagy in osteosarcoma. The data with LM7 cells are in line with other studies that
have firmly established the induction of cytoprotective autophagy with either DOX or
CDDP in osteosarcoma cell lines. We found that in CCH-OS-D cells autophagy
inhibition with HCQ prior to DOX treatment resulted in increased cell viability
suggesting a cytotoxic role for autophagy in this context. This presents a valuable model
system for evaluating the mechanisms of cytoprotective vs cytotoxic autophagy and for
exploring the effects of autophagy modulation. Additional studies are needed to confirm
these findings. While we have shown this duality in other osteosarcoma cell lines and
with various chemotherapeutic agents, these findings would benefit greatly from
validation in vivo.
Post-treatment phosphorylated HSP27 expression correlates with the role of autophagy
and effect of autophagy inhibition in osteosarcoma cells
Previously, we identified that treatment of LM7 and CCH-OS-D cells with GCB
resulted in opposing effects of autophagy. A human phosphokinase array was used to
identify differentially expressed proteins and phosphoproteins that could serve as
potential biomarkers and to gain mechanistic insights into the opposing roles of
chemotherapy-induced autophagy. Post-treatment expression of pHSP27 correlated with
the role of autophagy and effect of autophagy inhibition independent of cell line, species
of origin (murine or human osteosarcoma), or chemotherapeutic agent. An increase in
pHSP27 (but not total HSP27) following chemotherapy correlated with a cytoprotective
role for autophagy and therefore was associated with a benefit to adding HCQ to
chemotherapy. Decreased expression of pHSP27 following treatment correlated with
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cytotoxic autophagy and alternate cell death. In this setting, the addition of HCQ was
associated with increased cell viability. These findings may have important biomarker
implications for the treatment of patients with osteosarcoma with autophagy inhibitors.
We therefore sought to validate these findings in osteosarcoma cells following treatment
with standard chemotherapy, DOX and CDDP.
LM7 and CCHOSD cells were treated with DOX or CDDP for 48 hours;
untreated cells were used as a control. Phosphoprotein expression was determined using
the human phosphokinase antibody array kit (R&D Systems) and analyzed by
densitometry. Multiple phosphoproteins demonstrated changes in expression following
treatment with chemotherapy (data not shown).

Specifically, pHSP27 (s78/82) was

decreased in CCHOSD cells following DOX or CDDP and increased in LM7 with both
agents (Figure 26). In comparison, heat shock protein 60 (HSP60) was increased with
DOXO in both cells lines and relatively unchanged following CDDP treatment.
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Figure 26. Post-treatment expression of phosphorylated HSP27 varies by osteosarcoma
cell line. LM7 and CCH-OS-D cells were treated with DOX (0.2ug/mL) or CDDP (20
uM) for 48 hours. Proteins were detected using a human phosphokinase antibody array
kit (R&D Systems). DOX and CDDP resulted in increased expression of pHSP27 (red
boxes, left; relative densitometry, right) in LM7 cells as compared to untreated controls.
Conversely, pHSP27 expression was decreased in CCH-OS-D treated with DOX or
CDDP.
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These findings are consistent with prior work from our lab, demonstrating
induction of pHSP27 following treatment correlated with a cytprotective role of
autophagy in osteosarcoma. However, the limited number of replicates and
semiquantitative approach did not allow for evaluating the statistical significance of these
findings. Functional proteomic profiling by reverse phase protein lysate array is currently
underway for both cell lines treated with DOX, CDDP, and GCB to validate these
findings. This platform includes a panel of >290 proteins and phosphoproteins including
HSP72, pHSP27, HMGB1, as well as other key autophagy-related and apoptotic pathway
proteins. These studies will allow for further exploration of specific pathways associated
with cytotoxic vs cytoprotective autophagy in osteosarcoma.
Summary of in vitro Studies
Both doxorubicin and cisplatin are able to induce autophagy in LM7 and CCHOS-D cell lines, however the dose and time point for maximal chemotherapy-induced
autophagy or increased autophagic flux may vary depending on the cell line or
chemotherapeutic agent used. Further, autophagy inhibition can result in either increased
chemosensitivity and decreased viability (in the case of doxorubicin or cisplatin in LM7)
or alternatively, can reduce chemosensitivity and increase viability (for doxorubicin in
CCH-OS-D). These findings imply a dual role for chemotherapy-induced autophagy in
osteosarcoma, either as a cytoprotective mechanism promoting cell survival or cytotoxic
leading to cell death. Finally, we demonstrated that the post-treatment expression of
pHSP27 correlated with the role of autophagy and effect of autophagy inhibition. In LM7
cells, doxorubicin and cisplatin result in increased expression of pHSP27 and induction
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of cytoprotective autophagy. In CCH-OS-D where autophagy appears to be cytotoxic,
pHSP27 expression decreases following doxorubicin exposure. These findings are
summarized in Table 21.

LM7

CCHOSD

Doxorubicin
Autophagy

Cisplatin

Doxorubicin

Cisplatin

Varying degrees of autophagy induction in both cell lines with both agents

Effect of autophagy
inhibition

Decreased viability

Decreased viability

Increased viability

No change in
viability

Post-treatment
pHSP27 expression

Increased

Increased

Decrease

Decrease

Cell survival

Cell survival

Cell death

No effect

Proposed Role of
Autophagy

Table 21. Summary of in vitro studies.
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IV. Discussion
The paradoxical role of autophagy in cancer has been well described, however the
key determinants of autophagy as either a mechanism of chemoresistance or promoting
cancer cell death have not been defined. Defining the role of autophagy in a specific
context and identifying potential biomarkers that could therefore predict benefit (or
potentially harm) for combining autophagy inhibitors with cytotoxic chemotherapy is
needed. In this project, we sought to understand the role and prognostic significance of
chemotherapy-induced autophagy in osteosarcoma patients treated with standard MAP
chemotherapy as well as in osteosarcoma cell lines and to correlate these findings with
expression of HSP27/pHSP27.
First, we show that both cytoplasmic LC3B puncta and HSP27 expression are
relevant prognostic biomarkers in patients with localized osteosarcoma. Patients that lack
LC3B+ puncta (<10% of cells) at resection following preoperative chemotherapy have a
poor prognosis, as did patients who expressed HSP27 (>10% of cells). By combining
these 2 markers at resection, we were able to identify a favorable risk group (HSP27/LC3B+) and those with particularly poor risk (HSP27+/LC3B-) with standard therapy.
These markers may be valuable in risk stratification and support the development of
clinical trials targeting either HSP27 or modulating autophagy in osteosarcoma.
Although several studies have examined the role of chemotherapy-induced
autophagy in osteosarcoma cell lines, to our knowledge, the presence and prognostic
significance of autophagy markers such as LC3B has not been previously reported in
osteosarcoma patients. While the majority of preclinical data suggest that chemotherapy-
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induced autophagy is a mechanism of chemoresistance to standard MAP chemotherapy in
osteosarcoma,65, 70, 101 and the expression LC3B has been shown to be a poor prognostic
marker in multiple other cancer types,102 we found the opposite. The presence of LC3B
puncta following chemotherapy was a positive prognostic marker in osteosarcoma. One
large study of >1600 breast cancer patients similarly showed the presence of cytoplasmic
LC3B to be a favorable prognostic marker following adjuvant chemotherapy.56 Using a
similar methodology to evaluate LC3B puncta in tumor cells and the same >10% cutoff,
Laoire et al demonstrated that the combined positivity to LC3B+ puncta and presence of
nuclear HMGB1 was associated with prolonged metastasis-free and breast cancer specific
survival. Additionally, the authors showed that LC3B+ puncta correlated with a reduction
in SQSTM1/p62, suggesting that a high percentage of LC3B+ puncta reflects increased
autophagic flux.
In our study, a limited number of patients demonstrated LC3B puncta on pretreatment specimens suggestive of basal autophagy in a subset of primary osteosarcoma.
However, this finding was not associated with relapse-free survival, overall survival, or
pathologic treatment response. Overall, the proportion of osteosarcoma with LC3B+
puncta was significantly higher in post-treatment specimens, though the majority of these
specimens were not paired. In the nine patients with paired pre-/post-chemotherapy
specimens who were initially negative for cytoplasmic LC3Bpuncta, >50% were positive
following chemotherapy. Taken together, these findings suggest that standard
chemotherapy can induce autophagy in a subset of patients with osteosarcoma and that
chemotherapy-induced autophagy may be favorable in the primary treatment of
osteosarcoma. The presence of LC3B+ either prior to treatment or at resection did not
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correlate with percent tumor necrosis nor was it significantly associated with a “good”
pathologic response, suggesting that LC3B+ is an independent prognostic biomarker
rather than a surrogate marker for pathologic treatment response. Even amongst the
subset of poor responders, patients lacking LC3B following chemotherapy had a trend
towards inferior overall survival.
The association of post-treatment LC3B puncta and favorable outcomes suggests
that chemotherapy-induced autophagy following MAP may serve as mechanism of
alternate cell death as opposed to chemoresistance in primary osteosarcoma. Rather than
combining chemotherapy with autophagy inhibitors,2,
autophagy such as mTOR inhibition103,
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66, 67, 69, 71

strategies that induce

or other agents58 that are currently being

explored in osteosarcoma may prove beneficial when added to primary therapy. The
implications

for targeting autophagy (either promoting or inhibiting it) in

recurrent/metastatic osteosarcoma remain unclear. LC3B puncta was observed in the
majority of metastasis specimens (67%). Further, in a limited number of metachronous
biopsy-metastasis and resection-metastasis pairs, LC3B became positive in the majority
of patients who were initially scored as negative. Given the conflicting data regarding the
association of LC3B puncta with improved relapse free and overall survival but its
increased occurrence in osteosarcoma metastasis, it would be premature to conclude
whether autophagy, as evidenced by LC3B, is a driver of osteosarcoma metastasis and
therefore should be inhibited. Additional mechanistic studies are needed.
In regard to HSP27, our study is in agreement with prior studies that have shown
overexpression of HSP27+ at biopsy as an independent poor prognostic factor.89,
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However, in these 2 small series the proportion of HSP27+ tumors (>10% of tumor cells)
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was much lower both at biopsy (22-24%) and resection (33-37%) as compared to our
finding (85% and 52%, respectively). While Uozaki et al found an association between
HSP27+ at resection and poor response among 19 patients evaluated, HSP27+ did not
correlate with pathologic treatment response in our analysis. Although not a predictive
biomarker of pathologic response, the negative prognostic implications of HSP27
overexpression at diagnosis support strategies combining HSP27 inhibition with primary
MAP chemotherapy. Several preclinical studies support the rationale for targeting HSP27
in osteosarcoma.105-107
We examined the combination of HSP27 and LC3B in osteosarcoma patient
samples based upon preclinical data suggesting an association between HSP27, pHSP27,
and autophagy. The ER stress response/ubiquitin-proteosome system, mitochondrial
autophagy (mitophagy), and the Akt/mTOR pathway have been proposed as mechanisms
linking HSP27 and autophagy.108,
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In addition, HMGB1 which has been shown to

promote drug resistance in osteosarcoma cell lines by inducing autophagy, regulates the
expression HSP27. 108
In osteosarcoma cell lines, both doxorubicin and cisplatin can induce autophagy.
However, this may lead to either cell survival or cell death and therefore opposing effects
of autophagy inhibition. We previously demonstrated that increased expression of
pHSP27 following chemotherapy exposure was associated with cytoprotecitve autophagy
and chemoresistance.73 Here we found consistent findings when LM7 and CCH-OS-D
cells were treated with either doxorubicin or cisplatin. Notably, however, the association
between the role of autophagy, effect of autophagy inhibition, and total HSP27 in
osteosarcoma cell lines has been inconsistent. We sought to evaluate pHSP27 in
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osteosarcoma tumor specimens based upon the initial hypothesis but labeling was
severely limited likely due to the decalcification protocols used in processing bone tumor
specimens in FFPE tissue. We found no correlation between the LC3B puncta and
HSP27+ in patient specimens.
There are several limitations to the current study. In regard to the biomarker
analysis, all samples were analyzed retrospectively from a single institution and there
were a limited number of pretreatment biopsy specimens. This significantly limited the
number of pre-treatment/post-treatment paired samples available for analysis and
therefore limited our ability to specifically assess chemotherapy-induced autophagy.
Further, based upon the initial hypothesis and cell line data, we sought to explore pre/post-treatment changes in HSP27 and pHSP27 expression (rather than absolute
expression) in relation to autophagy markers. This analysis could not be conducted given
the lack of paired samples and our inability to accurately measure pHSP27 in decalcified
bone tumor specimens. Finally, autophagy was assessed by a single marker, LC3B
puncta. The addition of other autophagy markers such as p62 to confirm the presence of
autophagic flux or the autophagy-related DNA binding protein HMB1 to this analysis
would serve to validate these findings and is currently underway.
In regard to analysis of chemotherapy-induced autophagy in osteosarcoma cell
lines, optimal conditions for autophagy induction with doxorubicin and cisplatin in LM7
cells were not defined. While both agents were shown to induce some degree of
autophagy, insufficient autophagy induction may limit the implications of the viability
studies and post-treatment pHSP27 expression data. Finally, while we have demonstrated
a correlation between the role of chemotherapy-induced autophagy and pHSP27 in
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osteosarcoma cell lines, the functional significance and potential mechanistic basis of
these findings have not been explored.
This study adds to our prior work identifying a context-dependent dual role for
chemotherapy-induced autophagy in osteosarcoma that is independent of cell line,
species of origin, or chemotherapeutic agent. These findings establish a valuable model
system to further evaluate the mechanisms underlying of cytotoxic vs. cytoprotective
autophagy. While pHSP27 was initially identified as a differentially expressed protein
that consistently correlates with the role of autophagy, its functional significance remains
unclear. Future studies stemming from this project will undertake functional proteomic
profiling by RPPA to identify additional proteins and key pathways associated with the
opposing effects of autophagy as well as functional studies using shHSP27 knockdowns
in LM7 and overexpression of HSP27 in CCH-OS-D cells to determine if HSP27 is
indeed necessary for cytoprotective autophagy in osteosarcoma. Given that pHSP27 (but
not total HSP27) correlates with the role of autophagy, identifying the specific kinases
involved in phosphorylating HSP27 in each context may give additional mechanistic
insights. Finally, in vivo studies combining autophagy inhibitors with chemotherapy in
the treatment of osteosarcoma will be a key step in translating these findings to the clinic.
Independent of their potential mechanistic link, HSP27 and LC3B can be
considered as independent biomarkers in osteosarcoma; if analyzed together they allow
for improved risk stratification for localized osteosarcoma patients following
preoperative chemotherapy. One of the limitations of this approach, however, is awaiting
evaluation of these markers at resection ~12 weeks into therapy. Predictive biomarkers of
response to conventional MAP chemotherapy are needed. Such markers would allow for
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modification or intensification of preoperative therapy for poor risk patients in a window
trial paradigm that would allow for paired biomarker assessment. Prospective analysis of
paired-samples may be beneficial in validating HSP27 and LC3B puncta as prognostic
and potentially as predictive biomarkers in osteosarcoma. This would justify the addition
of HSP27 targeted therapies or agents that promote autophagy to standard chemotherapy
in poor risk patients.

V. Conclusions
While previously thought to be primarily a mechanism of chemoresistance,
chemotherapy-induced autophagy can serve a dual role in osteosarcoma. Autophagy
following standard chemotherapy as evidenced by the presence of LCB puncta in
osteosarcoma tumor cells is associated with favorable outcomes. Conversely,
overexpression of HSP27 is a negative prognostic marker prior to treatment or following
preoperative chemotherapy. When evaluated together, the combination of LC3B/HSP27+ identifies particularly poor risk patients following preoperative chemotherapy.
These findings not only establish HSP27 and LC3B as prognostic biomarkers in
osteosarcoma but serve as a rationale for future studies targeting either HSP27 or
modulating autophagy in osteosarcoma treatment.
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